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ABSTRACT 
New antimicrobial compounds are urgently needed to fight infective diseases caused 
by antibiotic-resistant human pathogens. Promising candidates are host defense 
peptides (HDPs), also known as antimicrobial peptides (AMPs), essential component 
of innate immunity in eukaryotes. Due to their biochemical properties (high content of 
basic and hydrophobic residues), they selectively bind and disrupt bacterial 
membranes that are rich in anionic lipids. In addition, many AMPs display 
immunomodulatory functions. This peculiar combination of biological activities makes 
AMPs very promising therapeutic agents. Surprisingly, many human proteins with 
functions not necessarily related to host defense can behave as sources of AMPs. 
Some examples are lactoferrin, lysozyme and thrombin. Since these AMPs are 
hidden in large proteins, they can be defined as “cryptic”. In order to identify by a 
rational approach further human proteins carrying cryptic AMPs, an in silico 
screening method that allows to localize antimicrobial regions hidden inside the 
primary structure of precursors was developed. A wide list of potential new AMPs 
was obtained using this method to analyze about 4’000 human extracellular proteins. 
This list represented the starting point of the present PhD project. The main aim was 
to select and characterize the most pharmacologically interesting potential AMPs in 
order to find candidates suited for the development of novel human antimicrobial and 
anti-inflammatory agents. Such peptides might be used for topical treatments, like 
treatment of surgical wounds and ulcers, and for the infections of skin, mouth and 
airways. Firstly, I developed a novel cost-effective fusion system, particularly well-
suited for the production of toxic peptides in E. coli. To avoid AMPs toxicity toward 
bacterial host, I rationally designed a carrier protein starting from a Rana pipiens 
ribonuclease, named onconase (ONC), that is expressed at high level (200 mg/L of 
culture) as inclusion bodies in E. coli. In order to optimize this method, a well-known 
AMP derived from human thrombin, named GKY20 was used as model peptide. After 
acid cleavage of Asp-Pro bond inserted at carrier-peptide junction, the carrier protein 
was removed by selective precipitation at neutral pH. Peptide (P)GKY20 (so called 
as it has an additional proline at N-terminus) was recovered with yields of 10-15 mg/L 
of culture. Moreover, I demonstrated that this strategy also allows to prepare 
peptides with a N-terminal cysteine residues that could find many applications in 
basic and applied research like for example preparation of labeled peptides, protein 
ligation for the semi-synthesis of modified proteins, immobilization on supports etc. 
Using our improved carrier several newly identified putative AMPs from 20 to almost 
50 amino acids were successfully produced with yields even higher than that of 
(P)GKY20 (up to 30 mg/L of culture in the case of a 47 residues long peptide derived 
from pepsinogen A3). Therefore, our method is complementary to chemical synthesis 
being particularly well-suited to prepare peptide longer than 20-25 residues. All these 
peptides showed, as expected, antimicrobial activity on GRAM-negative and GRAM-
positive strains with MIC values in the micromolar range thus validating the efficacy 
of the bioinformatic screening method. Interestingly, some of them prevented P. 
aeruginosa biofilm formation at concentration lower than MIC values. Moreover, we 
found that four of our peptides possess very interesting anti-inflammatory properties 
(e.g. the ability to reduce release of pro-inflammatory cytokines). Very interestingly, 
they proved to be non-toxic for eukaryotic cells thus suggesting that these peptides 
could be used as drugs. Even if at the moment the panel of peptides and of the 
assays performed is limited, our data suggest that the in silico-derived list of potential 
AMPs is a rich source of peptides with pharmacologically relevant properties. 
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RIASSUNTO  
La diffusione di ceppi patogeni per l’uomo dotati di resistenze multiple agli antibiotici 
convenzionali (fenomeno dell’antibiotico-resistenza) costituisce un grave problema 
per la salute umana, come evidenziato nell’ultimo rapporto dell’Agenzia Mondiale 
della Sanità (2015). Negli ultimi decenni a suscitare maggiore preoccupazione sono 
stati i ceppi resistenti alla meticillina o alla vancomicina appartenenti al genere 
Staphylococcus oltre che batteri Gram negativi appartenenti ai generi Escherichia, 
Pseudomonas, Acinetobacter ecc. Per combattere il fenomeno dell’antibiotico-
resistenza, sono necessarie nuove classi di antimicrobici che garantiscano 
un’efficacia duratura nel tempo. Candidati ideali sono i Peptidi AntiMicrobici cationici 
(AMP). Tali molecole, sono presenti in quasi tutte le forme di vita -batteri inclusi- e 
rappresentano la più antica arma di difesa del sistema immunitario innato. 
Inizialmente scoperti per la loro attività antimicrobica ad ampio spettro, hanno 
suscitato sempre più attenzione anche per gli interessanti ruoli fisiologici che 
rivestono nei meccanismi dell’immunità innata. Per tale motivo sono spesso definiti, 
in senso più ampio, peptidi della difesa dell’ospite (HDP, dall’inglese Host defense 
peptides). 
Sebbene siano una classe di molecole molto eterogenea in termini di lunghezza e 
struttura secondaria, gli AMP possiedono caratteristiche chimico-fisiche comuni, quali 
la carica netta positiva  a pH fisiologico (di solito da +3 a +7), e l’elevato contenuto di 
residui idrofobici (≥ 30 %). Tali proprietà sono alla base del loro peculiare 
meccanismo d’azione. Funzionalmente, gli AMP differiscono dalla maggior parte 
degli antibiotici convenzionali per quanto riguarda il loro “bersaglio molecolare”. Nel 
caso degli antibiotici convenzionali il bersaglio è generalmente una (macro)molecola 
specifica del batterio. Nel caso dei peptidi antimicrobici il principale, anche se non 
l’unico, “bersaglio” è rappresentato dalla membrana batterica (interna e/o esterna). 
La prima fase di interazione peptide cationico/membrana è mediata dalla presenza di 
fosfolipidi anionici, come fosfatidilglicerolo e cardiolipina, distribuiti abbondantemente 
su entrambi i lati della membrana batterica, sia nei batteri Gram positivi che nei Gram 
negativi. In seguito, il peptide adotta una conformazione anfipatica che gli consente 
di inserirsi nella membrana. Si innescano così una serie di eventi che comportano la 
perdita delle funzioni fisiologiche della membrana (alterazioni di fluidità, di spessore, 
di permeabilità selettiva ecc.). Alcuni peptidi, tuttavia, danneggiano le cellule anche 
attraversando la membrana e attaccando bersagli intracellulari, come nel caso della 
buforina II capace di legare il DNA. La tossicità selettiva nei confronti dei batteri è 
legata alla differente composizione lipidica. Infatti negli eucarioti il foglietto esterno 
della membrana plasmatica contiene quasi esclusivamente lipidi zwitterionici mentre 
quelli anionici sono confinati nel foglietto citosolico, pertanto gli AMP non riescono a 
legarsi ed inserirsi efficientemente nelle membrane eucariotiche. 
A causa del loro peculiare meccanismo di azione è improbabile che i batteri possano 
sviluppare una completa resistenza, ciò, infatti, richiederebbe un sostanziale 
cambiamento nella composizione di membrana che potrebbe avere “costi” metabolici 
troppo elevati per i batteri. Basti pensare che le membrane batteriche sono coinvolte 
in ruoli metabolici fondamentali, come le catene di trasporto degli elettroni e la 
produzione di ATP. 
Oltre all’ attività antimicrobica diretta, gli AMP fungono anche da molecole ponte tra i 
meccanismi dell’immunità innata e quella acquisita. Alcuni noti peptidi antimicrobici 
umani come α e β defensine e LL-37, l’unica catelicidina umana, sono dotati di 
diverse proprietà immunomodulanti che si aggiungono alla loro efficacia come 
antimicrobici. Ad esempio possono reclutare le cellule effettrici dell’immunità innata  
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nei siti di infezione (chemiotassi dei macrofagi) ed attivare le cellule specializzate 
coinvolte nei meccanismi dell’immunità adattativa (cellule dendritiche immature, 
cellule T immature).  
In aggiunta ai già citati AMP convenzionali, negli ultimi decenni sono state descritte 
numerose proteine eucariotiche, non strettamente legate alla difesa dell’ospite, che si 
comportano come “contenitori” o vettori di AMP. Ne sono esempi il lisozima, la 
lattoferrina, le apolipoproteine, la trombina etc.. 
Ad esempio, la lattoferrina, esplica attività antimicrobica agendo come potente 
chelante del ferro, un nutriente essenziale per i microrganismi. Tuttavia nello 
stomaco del neonato essa viene proteolizzata dalla pepsina che causa il rilascio, 
dalla regione N-terminale, di un peptide antimicrobico di 25 residui denominato 
“lactoferricina” più attivo di quanto non lo sia la lattoferrina stessa nei confronti di 
svariati ceppi. Secondo un modello molto suggestivo quando tali proteine vengono a 
contatto con i batteri, l’azione delle proteasi batteriche, eventualmente combinata a 
quella di proteasi dell’ospite, permetterebbe il rilascio di regioni che, una volta libere 
dai vincoli conformazionali della proteina nativa, diventerebbero dei veri e propri 
AMP. Dunque, tali peptidi potrebbero essere definti “AMP criptici”.  
Preliminarmente alle attività del presente progetto di dottorato, al fine di ricercare con 
un approccio più razionale peptidi “criptici” presenti nel secretoma umano, è stato 
sviluppato dal Dott. Notomista, un metodo bioinformatico che consente di localizzare 
regioni antimicrobiche in precursori proteici e di fornire una predizione quantitativa 
dell’attività antibatterica associata ad esse. Mediante tale approccio, sono state 
analizzate circa 4’000 proteine extracellulari umane ed è stata così creata una lista di 
potenziali AMP. Il presente lavoro di tesi si colloca all’interno di una vasta linea di 
ricerca il cui obiettivo principale è l’isolamento e la caratterizzazione degli AMP 
umani più interessanti suggeriti dalla predizione bioinformatica, al fine di selezionare 
candidati ideali per lo sviluppo di nuovi agenti antimicrobici ed antinfiammatori ad uso 
topico impiegabili nel trattamento di ferite chirurgiche, ulcere cutanee e delle mucose, 
infezioni delle vie aeree come sinusiti ed otiti etc.  
Pertanto, gli obiettivi del presente lavoro di tesi possono essere riassunti in tre punti 
fondamentali: 
i) lo sviluppo ed ottimizzazione di un nuovo sistema di espressione di AMP in E. 
coli;  
ii) la produzione e la caratterizzazione dei peptidi più interessanti presenti nella 
lista di potenziali AMP umani generata dal metodo bioinformatico; 
iii) la caratterizzazione funzionale completa di alcuni dei peptidi più promettenti. 
 
i) Sviluppo di un nuovo sistema di espressione di peptidi tossici in E. coli 
L’accurata caratterizzazione delle proprietà farmacologicamente rilevanti dei 
potenziali AMP umani ha richiesto innanzitutto lo sviluppo di un metodo efficace e 
relativamente economico per la loro produzione. La sintesi chimica è particolarmente 
idonea per la produzione di peptidi di dimensioni ≤ 25 residui e quando sono 
necessarie soltanto piccole quantità (tra i 5-10 mg). Tuttavia, per la sintesi di peptidi 
relativamente lunghi (≥ 25 residui) e necessari in quantità maggiori, i metodi di 
produzione biologica posso rivelarsi più economici ed utili alla produzione su larga 
scala. 
Il nuovo metodo di espressione sviluppato, si basa sull’utilizzo di una proteina carrier 
progettata razionalmente a partire da una ribonucleasi di Rana pipiens chiamata 
onconasi (ONC). Tale proteina presenta diverse caratteristiche che la rendono un 
partner ideale: i) elevati livelli di espressione (circa 200 mg/L di coltura); ii) capacità 
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di formare corpi d’inclusione mascherando quindi la tossicità del peptide nella 
proteina di fusione ONC-peptide; iii) piccole dimensioni (104 amminoacidi) che 
consentono elevate rese di peptide in seguito al rilascio dal partner; iv) solubilità 
dipendente dal pH. Infatti, la proteina ONC denaturata è solubile a pH inferiore a 4 
ma a pH neutro forma aggregati macroscopici insolubili. Questa caratteristica 
rappresenta un grande punto di forza del metodo sviluppato, in quanto consente una 
purificazione semplice di peptidi solubili a pH 7. 
L’efficienza del sistema di fusione è stata valutata clonando a valle della proteina 
carrier la sequenza di un AMP criptico già caratterizzato in letteratura, il peptide 
GKY20, derivante dall’estremità C-terminale della trombina umana.  
Tra la proteina carrier ed il peptide è stato inserito come sito di taglio la sequenza 
acido labile Asp-Pro. Quindi, l’idrolisi acida rilascia un peptide dotato di un residuo di 
prolina addizionale all’estremità N-terminale.  
Per evitare le reazioni indesiderate, come la modifica delle catene laterali, che 
possono verificarsi utilizzando acidi concentrati come l’acido formico (al 50-70%), è 
stato sviluppato ed ottimizzato un metodo di idrolisi acida in condizioni blande. 
L’ottimizzazione di tale sistema di taglio, ha rilevato risultati inattesi ed al contempo 
interessanti. Infatti, tutti i siti Asp-X presenti in ONC sono risultati sensibili all’idrolisi 
acida, seppure in misura differente. Di particolare interesse è stata la scoperta 
dell’elevata efficienza di idrolisi acida delle sequenze Asp-Cys, non ancora nota in 
letteratura.  
In aggiunta ai frammenti aspecifici rilasciati dall’ONC, si è anche osservato che 
alcune proteine contaminanti di E. coli rilasciavano frammenti durante l’idrolisi acida 
che rendevano più complicata la successiva purificazione del peptide. Pertanto al 
fine di ottenere una versione migliorata della proteina carrier sono state introdotte 
diverse mutazioni. La versione finale della proteina, chiamata ONC-DCless-H6, è 
priva di residui di acido aspartico, cisteina e metionina ed è dotata di una sequenza 
di residui di istidina (His-Tag) che consente una più rapida purificazione del costrutto 
di fusione dalle proteine contaminanti di E.coli. Inoltre  ONC-DCless-H6 si esprime 
con livelli simili o maggiori a ONC-(P)GKY20 ed è presente esclusivamente nella 
frazione insolubile di E. coli, dimostrando che le mutazioni scelte non alterano le 
proprietà caratteristiche dell’ONC. Mediante ONC-DCless-H6, è stato prodotto il 
peptide (P)GKY20 ad elevate rese (10-15 mg/L di coltura). Tale peptide, è stato 
separato dalla proteina di fusione attraverso idrolisi acida e purificato mediante 
precipitazione selettiva del carrier. Il grado di purezza di (P)GKY20, analizzato 
mediante HPLC è ≥ 95%, indicando che nessun ulteriore passaggio cromatografico 
era necessario. Va sottolineato che il peptide ricombinante (P)GKY20 ha attività 
antimicrobica identica a quella del peptide GKY20 sintetico (con valori MIC simili su 8 
ceppi). Pertanto si può concludere che il residuo di prolina addizionale all’N- 
terminale del peptide ricombinante non altera la sua attività antimicrobica.  
In base alle osservazioni ottenute nella fase di ottimizzazione dell’idrolisi acida, si è 
pensato di sostituire il sito di taglio Asp-Pro nella giunzione carrier-peptide con il sito 
acido labile Asp-Cys, per produrre il peptide ricombinante GKY20 dotato di un 
residuo di cisteina all’N-terminale. Il peptide (C)GKY20 è stato coniugato ad un 
fluoroforo dotato di gruppo maleimide sfruttando la peculiare reattività del gruppo 
tiolico della cisteina. Questo peptide marcato potrà essere utilizzato per studi di 
localizzazione cellulare, interazione con gli LPS e i liposomi ecc.. 
Incoraggiati dai risultati ottenuti con il nuovo sistema di espressione, alcuni degli 
AMP più promettenti sono stati prodotti in forma ricombinante. Tutti i peptidi sinora 
selezionati sono stati prodotti con rese simili o maggiori a (P)GKY20. 
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ii) Produzione di potenziali peptidi antimicrobici umani 
L’analisi bioinformatica ha permesso di stilare una lista di potenziali AMP contenuti in 
proteine coinvolte nella coagulazione, proteine sieriche, della matrice extracellulare 
etc. In questa lunga lista ho selezionato due peptidi particolarmente interessanti per 
motivi differenti: il peptide di attivazione dell’isoforma A3 del pepsinogeno umano 
[PA-3(1-47)] e gli ultimi 28 amminoacidi all’estremità C-terminale del β Fibrinogeno 
umano [βFib(420-447)]. 
PA-3(1-47) viene rilasciato dal pepsinogeno mediante proteolisi operata dalla pepsina. 
Questo taglio è essenziale per la produzione della pepsina matura. Finora l’unica 
funzione descritta in letteratura per PA-3(1-47) è infatti mediare la secrezione della 
pepsina.  
Il peptide PA-3(1-47), è stato preparato in forma ricombinante [(P)PA 3(1-47)] mediante il 
metodo descritto per (P)GKY20, con rese anche più elevate (circa 30 mg/L di 
coltura). Con lo stesso metodo sono stati prodotti anche (P)PA-3(1-25) e (P)PA-3(26-47), 
due frammenti di PA-3(1-47), già descritti in letteratura, che sulla base dell’analisi 
bioinformatica potevano essere dotati di attività antimicrobica. Tutti e tre i peptidi, 
come predetto, hanno mostrato attività antimicrobica a concentrazioni micromolare 
verso ceppi batterici Gram negativi e Gram positivi. 
Il potenziale peptide al C-terminale del β Fibrinogeno umano è stato prodotto in due 
varianti, βFib(420-447) e βFib(425-447), entrambi ottenuti con rese simili a (P)GKY20 
ovvero 10 mg/L di coltura. 
 
iii) Caratterizzazione funzionale degli AMP umani più promettenti 
In aggiunta alla caratterizzazione dei peptidi ricombinanti è stata effettuata la 
caratterizzazione di cinque potenziali AMP prodotti mediante sintesi chimica: Apo 
E(133-150), frammento dell’apolipoproteina E; Apo B(887-911) frammento 
dell’apolipoproteina B umana; PA-3(1-25) e PA-3(26-47), i frammenti del pepsinogeno 
sopra descritti; βFib(420-447), la regione C-terminale del fibrinogeno β prodotta anche in 
forma ricombinante. 
Questi peptidi sono stati caratterizzati per quanto riguarda le loro proprietà 
antimicrobiche, antibiofilm ed immunomodulanti durante il periodo di ricerca all’estero 
della durata di cinque mesi nei laboratori del prof. Robert Hancock (Università della 
British Columbia, Vancouver, Canada) la cui esperienza nel campo della 
caratterizzazione dei peptidi antimicrobici è ben nota. 
I risultati ottenuti hanno mostrato che tutti i peptidi in esame sono dotati di 
interessanti proprietà biologiche ma differenti da peptide a peptide. In particolare, il 
peptide derivato dall’apolipoproteina E mostra un ampio spettro di attività 
antimicrobica (con valori MIC al di sotto di 10 µM ) mentre βFib(420-447) risulta essere 
maggiormente attivo sui batteri Gram positivi, come ad esempio il ceppo MRSA di 
Staphylococcus aureus. Inoltre peptidi che possedevano moderata attività 
antimicrobica come quelli derivati da PA-3(1-47) e Apo B(887-911), hanno mostrato 
invece attività antibiofilm a concentrazioni alle quali non hanno avuto effetto sulle 
cellule in crescita planctonica. Inoltre, quasi tutti i peptidi analizzati presentano 
alcune proprietà tipiche degli AMP come per esempio la capacità di ridurre i livelli 
della citochina pro-infiammatoria TNF-α, innescati dalla stimolazione con i 
lipopolisaccaridi dei batteri Gram negativi. Tutti i peptidi analizzati ed in particolare il 
peptide βFib(420-447), inducono il rilascio della chemochina MCP-1 suggerendo un 
ruolo nella chemiotassi dei leucociti in aggiunta all’attività antimicrobica diretta. 
Complessivamente, tutti i peptidi studiati hanno mostrato in varia misura 
caratteristiche tipiche degli AMP. 
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Applicazioni biotecnologiche del presente lavoro di tesi 
Le peculiari caratteristiche degli AMP li rendono candidati particolarmente 
promettenti per lo sviluppo di nuovi agenti anti-infettivi: 
i. Possiedono un ampio spettro d’azione poiché agiscono contro batteri, virus, 
lieviti e funghi; 
ii. Sono selettivamente tossici per le cellule microbiche senza avere effetti 
dannosi per le cellule eucariotiche; 
iii. Non possiedono bersagli molecolari definiti, ma in generale danneggiano le 
membrane batteriche riducendo quindi la probabilità che insorgano ceppi 
resistenti; 
iv. Sono in grado di agire sia sui batteri in crescita planctonica che in forma 
sessile (biofilm). 
 
Di particolare interesse è quest’ultimo punto, in quanto circa l’80% delle malattie 
infettive croniche per l’uomo sono provocate da batteri patogeni capaci di formare 
biofilm. Solo agenti battericidi specificamente attivi su cellule in stato stazionario o in 
lenta divisione come appunto gli AMP possono eradicare completamente il biofilm. In 
tal senso, possono rivelarsi utili anche “terapie combinate” basate sulla 
somministrazione di formulazioni contenenti un AMP ed un antibiotico convenzionale. 
Gli AMP trovano già impiego in vari campi inclusa l’industria alimentare, ne sono 
esempi la nisina noto conservante naturale, la gramicidina S e la polimixina utilizzati 
in creme ad uso topico e la lattoferrina presente nel latte in polvere. Tuttavia, il loro 
impiego in campo clinico rimane sicuramente una delle prospettive più interessanti. 
Ad oggi diversi AMP sono in fase di studio pre-clinico e clinico, principalmente come 
antimicrobici.  
La ricerca di candidati antimicrobici umani dotati di proprietà biologiche addizionali 
(spesso dipendenti da interazione con recettori specie-specifici) rende alcuni dei 
peptidi analizzati più promettenti e interessanti per lo sviluppo di nuovi agenti 
antimicrobici ed antinfiammatori. 
Il presente lavoro di dottorato ha contribuito alla validazione e ottimizzazione di due 
strumenti che potranno rivelarsi di grande utilità nello sviluppo delle applicazioni 
biotecnologiche degli AMP: un metodo bioinformatico utile per l’individuazione di 
potenziali nuovi AMP ed un sistema di espressione per AMP ricombinanti, efficiente 
e versatile che può essere considerato complementare alla sintesi chimica. 
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1.1 Antibiotic resistance 
The development of antibiotics is possibly one of humanity’s greatest achievements, 
contributing to significantly increased life expectancy compared to past generations.  
The vast majority of antibiotic classes in use today have been isolated in the golden 
era of antibiotic discovery (between the 1940s and 1970s ), mainly from soil 
Actinomyces. However, today, the evolution of antibiotic resistance by important 
human pathogens has rendered these original molecules and most of their 
successors largely ineffective [1-2]. 
The inappropriate and/or overuse of antibiotics, in agriculture and industry 
contributes to accelerate the development of antibiotic resistance. As a result, many 
pathogenic strains have become “multidrug resistant” (MDR) i.e. resistant to three or 
more antibacterial drug classes [3]. 
Antibiotic-resistant pathogens emerging as major threats to public health, according 
to the 2014 report of global antibiotic resistance, published by the World Health 
Organization (WHO), are the following [4]:  
i) methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin 
resistant Staphylococcus aureus (VRSA);  
ii)  multidrug-resistant (MDR) Gram-negative bacteria such as Acinetobacter 
baumannii, Escherichia coli, Klebsiella pneumoniae and Pseudomonas 
aeruginosa;  
iii)  MDR strains of Mycobacterium tuberculosis which are a rising threat in the 
developing world [3]. 
The ability of these MDR bacteria to resist the effects of antibiotics generally depends 
on the following genetic strategies [5]: 
 producing destructive enzymes to neutralize antibiotics; 
 modifying antimicrobial targets, by mutations; 
 removing antimicrobial agents by efflux pumps; 
 preventing antibiotics from entering by creating a “biofilm” ( i.e. a community of 
bacterial cells enclosed in a self-produced polymeric matrix which confers 
protection against environmental stresses). 
The latter point is of particular interest since about 80% of infectious disease are 
complicated by involvement of biofilms [5].  
Therefore, huge efforts to develop new anti-infective strategies, without overlook also 
biofilm level resistance, are urgently required. Promising candidates are AntiMicrobial 
Peptides (AMPs), more accurately termed “Host Defense Peptides” (HDPs) to 
describe the variety of their activities correlated to innate immunity [6].  
 
1.2 General characteristics of host defense peptides  
HDPs are present in almost every life form -bacteria included- as Nature’s antibiotics 
[7-8] and represent the most ancient weapons of the innate immune system [9]. In 
mammals these peptides provide protection against a broad array of infectious 
agents: bacteria, viruses, fungi, yeasts and certain protists. 
They are an extremely heterogeneous group of defense molecules that vary in 
sequence, length and secondary structure.  
From the point of view of net charge, AMPs can be divided into anionic and cationic. 
Anionic AMPs are less common and generally not well characterized (noteworthy 
examples are dermcidin and SAAPs [10]). 
On the other hand, cationic AMPs are very common and hundreds of them have 
been characterized [11].Generally, they are small (from 12 to 50 amino acids), 
 8 
 
positively charged (under physiological condition from +5 to +8), with an unusual 
abundance of hydrophobic residues (≥30%) [7-8].  
Based on their structure, AMPs can be classified into four different classes: α-helical 
peptides (for example, LL-37,magainins and mellitin), β-sheets peptides stabilized by 
two to four disulfide bridges (for example, human α and β defensins); loop peptides 
with one disulfide bridge (for example, bactenecin); peptides enriched in amino acids 
like proline, tryptophan, histidine or glycine without a well defined structure (for 
example, indolicidin) (Fig. 1) [12]. 
The majority of AMPs are disordered in solution but, upon contact with bacterial 
membranes, they are able to fold into an amphipathic conformation [7-13]. 
 
 
 
 
 
 
 
 
 
Figure 1: Examples of secondary structure of antimicrobial peptides. 
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1.3 Mechanism of action 
The substantial differences existing between bacterial and eukaryotic cell 
membranes are the basis of AMPs interesting and selective mode of action. Indeed, 
in eukaryotic cell membranes, negatively charged phospholipids are sequestered in 
the inner leaflet of the lipid bilayer, whereas the outer leaflet is mainly composed of 
zwitterionic uncharged lipids [7-9-14]. In contrast, both Gram negative and Gram 
positive bacteria, have at least 15% anionic lipids in their membranes such as 
phosphatidylglycerol (PG) and cardiolipin (CL) (Fig.2) [14]. 
Although the exact nature of the mechanism of action of AMPs is still unclear, 
generally the overall positive charge is the driving force for the initial electrostatic 
interaction between cationic peptides and anionic microbial cell surface [7]. 
Successively, AMPs fold in an amphipathic conformation which allows their insertion 
into the membrane (Fig.3).  
 
 
 
 
 
 
 
 
 
Figure 2: Schematic representation of selective mode of action of antimicrobial peptides ( from 
Zasloff M.,2002). 
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Figure 3: Potential mechanism of membrane disruption and/or translocation by antimicrobial 
peptides. On the left AMP is represented as a ribbon diagram, with positively charged residues 
indicated in blue (other residues are shown in yellow). (a) The initial stages for many AMPs include 
membrane attachment (b) and then disruption of the membrane (c) or form pores. The panels on the 
right illustrate hypothetical mechanisms of the AMP–membrane interaction that can be studied by 
molecular dynamics simulations (from Fjell CD. et al., 2011). 
 
 
 
In contrast to conventional antibiotics, the development of AMPs resistance is very 
rare. It has been hypothesized that this depends on the fact that microbial cells might 
acquire resistance to AMPs only through modification of their membrane composition 
[7]. Such a change not only would require several mutations, but could also be 
detrimental to bacterial cells as their cytoplasmic membrane bears several essential 
metabolic functions including electron transport chains and ATP synthesis [7-16]. 
Although the acquisition of complete resistance against antimicrobial peptides is 
unlikely, some strains have acquired a limited resistance [17] by producing specific 
proteases like, for example, “omptins” of enterobacteria and V8 proteases of 
Staphylococcus ssp [18-19]. 
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1.4 Biological roles of HDPs 
Originally characterized as natural antimicrobial agents, it is increasingly appreciated 
that the main role of cationic peptides as host defense molecules may be to modulate 
the host immune response, a function complementary but independent from direct 
antimicrobial activity (Fig. 4).  
 
 
 
 
Figure 4: Biological roles of host defense peptide. Both direct antimicrobial killing and innate 
immune modulation occur with some peptides although certain peptides have one or the other activity 
preferentially (from Sahl G. and Hancock R.EW, 2006). 
 
 
Peptides endowed with direct antimicrobial activity as primary function, are often 
properly termed antimicrobial peptides (AMPs) [20]. However, increasing evidences 
show that many AMPs, have multiple additional roles in innate immunity, such as 
anti-inflammatory activity [21], stimulation of wound healing [22], angiogenesis [23-
24] and even anti-tumoral activity [25-26]. For this reason they are often referred to 
as host defense peptides (HDPs). In this regards, well-studied peptides are the two 
major classes of mammalian AMPs: defensins (which include the α, β and θ families) 
and cathelicidins with only one member in humans, the well-known peptide LL-37 
[27-28]. As for the latter peptide, its anti-infective mechanism of action in vivo, 
although still not completely clear, seems to be related to its ability to modulate 
immune cell-functions rather than to its moderate direct antimicrobial activity [28].  
Human major HDPs, are constitutively expressed in the granules of neutrophils ( α 
defensins and LL-37) and in the body most susceptible to infection, such as β 
defensins and LL-37 expressed in the mucosal epithelia and the skin [9]. However, 
they may be inducibly expressed in response to pathogenic challenge such as β 
defensin 2 (hBD-2 ) up-regulated during inflammation disorders [28].  
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1.4.1 Examples of direct antimicrobial activity 
Human defensins are an example of broad-range direct antimicrobial activity. Indeed 
they show antifungal activity against Candida albicans by lysing cells, in a manner 
similar to their antibacterial activity or exhibit strong viral-neutralizing activities 
avoiding viral entry or its intracellular shuttling [9]. There is no doubt that some 
peptides are present at concentrations suggesting that they act in a directly 
microbicidal fashion e.g. concentration of human α-defensins in neutrophil granules is 
estimated to be as great as 10 mg/ml. This would be sufficient to cause direct 
antimicrobial activity, despite the presence of divalent cations or other inhibitory 
substances [28]. On the other hand, it should be considered that body sites 
particularly sensitive to infections usually display a combination of several AMPs of 
different classes that may act additively or even synergistically. For example in 
human skin, at least four different classes of AMPs are co-expressed: LL-37, 
lysozyme, β-defensins and lactoferrin (Fig.5) [20-21]. 
 
 
 
 
 
 
 
Figure 5: A representative partial list of antimicrobial peptides (AMPs) produced by skin-
residing cells. hBD, human b-defensin; a-MSH, a-melanocyte- stimulating hormone; PSM, phenol-
soluble modulin; RNase, ribonucleotidase; SLPI, secretory leukocyte peptidase inhibitor (from 
Nakatsuji T. and Gallo R.,2011) 
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1.4.2 Examples of immune modulatory activity  
HDPs show additional biological properties involved in all stages of control and 
resolution of microbial infections and inflammation [21]. Studies on human and 
mouse cells have evidenced a variety of target cells stimulated by HDPs, including 
monocytes, macrophages, dendritic cells, epithelial cells, neutrophils, keratinocytes 
and others. The responses of these cells are often complex and dependent on the 
specific peptide, the type of cells, their activation state and the type of pathogen 
(Fig.6) [30]. For example, human α- and β-defensins can directly recruit leukocytes 
(by direct chemotaxis) or induce the expression of chemokines or cytokines including 
interleukin 8 (IL-8), MCP-1 (monocyte chemoattractant protein,) and interferon α 
(IFN-α), thereby indirectly promoting recruitment of effector cells ( by indirect 
chemotaxis) [28-30]. HDPs direct chemotactic activity, is very interesting since it is 
based on receptor-dependent mechanisms, as it has been demonstrated for LL-37. 
The neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide 
receptor-like 1 (FPRL1) as a receptor to chemo attract human peripheral blood 
neutrophils, monocytes, and T cells [31]. Furthermore, several HDPs act as anti-
inflammatory compounds during sepsis [32], protecting the host from potentially 
lethal effects resulting from an excessive Toll-Like Receptor-mediated inflammatory 
response induced by bacterial endotoxins, such as lipopolysaccharide (LPS) and 
lipoteicoic acid (LTA) of Gram negative and Gram positive bacteria, respectively. 
HDPs act both directly by binding and sequestering LPS and indirectly by altering 
gene expression of various inflammatory cells [28]. The endotoxin-neutralizing 
activity is typical of many well-known HDPs (LL-37 and pig protegrin-39) [22] but is 
also found in recently identified AMPs, derived from human thrombin, GKY20 [33].  
Finally, the biological activities of HDPs also include wound healing [22]. Very 
interestingly it has been demonstrated that cathelicidins can be used topically to 
stimulate wound healing in a diabetic mice model [29]. 
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Figure 6: Schematic representation of multiple action of antimicrobial peptides in host defense. 
AMP, anti-microbial peptide; DC, dendritic cell; LPS, lipopolysaccharide; pDC, plasmacytoid dendritic 
cell; PMN, polymorphonucleocyte; TLR, Toll-like receptor (from Lai Y. and Gallo R.,2009). 
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1.5. AMPs advantages as novel anti-infective agents 
The need of new antibiotics together with the knowledge of the broad and diverse 
biological functions of these endogenous peptides, have stimulated the interest in the 
development of AMPs as human therapeutics. They might be innovative anti-infective 
agents for several reasons: 
1. broad spectrum of antimicrobial activity ( including antifungal and antiviral); 
2. ability to modulate immune cell functions often receptor-mediated; 
3. low propensity for development of resistance; 
4. ability to act either on planktonic cell and on resting cells (such as biofilm). 
 
As regards point 4, it should be reminded that biofilm acts as a mechanical shield 
preventing antibiotic uptake, as shown for Pseudomonas aeruginosa biofilm, in the 
lung of immunocompromised patient of cystic fibrosis [34]. In this context, a 
promising potential application for AMPs is the enhancement of the potency of other 
antimicrobials: AMPs may facilitate access of conventional antibiotics into microbial 
cells, thus resulting in synergistic therapeutic effects [12-16]. A very interesting study 
demonstrated that biofilm of P. aeruginosa contains two subpopulations: a 
metabolically active subpopulation sensitive to tetracycline (an antibiotic) and a 
subpopulation with reduced metabolic activity sensitive to an AMP, colistin. 
Treatment with both tetracycline and colistin completely eradicate the biofilm [35]. 
 
1.6 Biotechnological application of AMPs 
AMPs biotechnological applications span from pharmaceutical industry to food 
industry. They are gaining attention mainly as antimicrobial alternatives; food 
preservatives and recently as immune defense regulators. Some AMPs, are already 
in phase II/III clinical trial as antimicrobials restricted to topical applications [6-12]. 
For anti-infective purpose, the first AMPs to be commercially manufactured were 
gramicidins produced by Bacillus brevis [20] used as antibiotics for topical 
applications. Other examples are nisin, approved since 1969 [36], and lactoferrin 
added to infant milk formula [37], both used in food industry as natural preservatives 
or dietary supplements. Currently, application of antimicrobial peptides in the medical 
field is still one of the most interesting perspective. The ability of HDPs to modulate 
the innate immune system has made them promising candidates also as vaccine 
adjuvants [6]. The inclusion of appropriate adjuvants in vaccines helps to improve 
their efficacy. Evidences are based on several observations such as human 
neutrophil defensins that can enhance both humoral and cell-mediated antigen-
specific immune response in murine models [38].  
Moreover, using natural peptides as templates, synthetic peptides have been 
designed that retain the immunomodulatory properties but lack unwanted effects like 
mast cell degranulation exerted by certain natural HDPs as for example the bovine 
peptide bactenecin. The resulting molecules, named IDR peptides (Innate defense 
regulators) boost protective immunity against infections without possessing direct 
antimicrobial action [39]. Nowadays many IDR-peptides are in clinical trial for topical 
application. An example is IMX-492 that has recently completed phase I clinical trials 
in patients with cancer chemotherapy-induced immune suppression [6-12]. Other 
peptides, such as MX-226 and Hlf1-11, were originally developed as antimicrobial 
peptides but later showed interesting immunomodulatory activities [6]. Thus, there 
are ample opportunities for AMPs development for clinic use as anti-infective agents.  
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1.7 Proteins carrier of cryptic AMPs 
Surprisingly, there are increasing evidences that many proteins whose functions are 
not necessarily related to host defense can act as sources of AMPs. 
Some examples are haemoglobin, thrombin, lactoferrin, lysozyme, histone-like 
proteins and vertebrate secretory ribonucleases [40-41-42]. Lysozyme is a well-
known example: it exerts bactericidal action by hydrolyzing peptidoglycan but, if 
inactivated by proteolysis, it releases AMPs [43]. Mammalian’s lactoferrin, a 
multifunctional protein, possesses bactericidal determinants at the N-terminus. 
Proteolysis in the stomach of infants leads to the release of peptides, which are more 
bactericidal than the corresponding native protein on several strains, including 
antibiotic resistant strains [44-45]. Furthermore, it has been demonstrated that 
human thrombin, a key enzyme in the coagulation cascade, contains bactericidal 
determinants in the C-terminal region (Fig.7) [33-46]. Human fibrinogen, another key 
protein in coagulation process, after incubation with thrombin, releases from its β 
chain a peptide with antimicrobial effects [47]. Also proteins commonly known for 
their role in lipid transport into blood such as Apoliporotein B [48] and Apolipoprotein 
E [49] possess hidden AMPs. These AMPs, being “hidden” in sequence of large 
proteins, can be defined “cryptic” AMPs. The discovery of so many cryptic AMPs has 
led to propose a very interesting hypothesis: as some bacterial strains have acquired 
a limited resistance to AMPs by producing specific proteases, in response, 
multicellular eukaryotes, have developed a panel of “AMP-Releasing Proteins” (AMP-
RPs) which release active peptides only after a partial proteolytic processing 
operated by bacterial and/or host proteases [50]. Thus, a bacterial strain that 
secretes proteases to protect from AMPs would "suicide” by releasing these “cryptic” 
AMPs from their precursors. This mechanism has been demonstrated for Zf-3, a 
ribonuclease from Danio rerio [51]. 
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Figure 7: A) 3D structure of human thrombin protein, the antimicrobial C-terminal region is 
coloured in red. B) Secondary structure of GKY20 peptide. C) Amino acid sequence of GKY20 
peptide. 
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1.8 A novel tool to identify new cryptic AMPs  
Even if several cryptic AMPs are now known, their discovery often has been 
accidental rather than the result of a rational approach. 
Moreover, it should be noted that the identification and the localization of a cryptic 
AMP inside its precursor is often carried out either through the analysis of peptide 
fragments generated by proteases, or by synthesizing a set of overlapping peptides 
which cover the entire sequence of the protein of interest. 
Such experimental procedures are expensive and time-consuming, and thus faster 
bioinformatic approaches, capable of highlighting the presence of a putative 
antimicrobial region, could prove extremely useful. 
In order to identify new hypothetical human AMPs by a rational approach, a novel 
bioinformatic method was developed by Dr. Notomista [52]. This method, based on a 
set of scoring functions, allows a semi-quantitative prediction of the antibacterial 
activity. This method was validated analyzing the sequence of known AMPs-
Releasing proteins thus, it is a promising tool to identify new human AMP-RPs. 
Moreover, as the method includes some strain-specific variables, it can be calibrated 
to predict efficacy on any desired bacterial strain. 
A first screening of about 4’000 human secreted proteins provided a list of potential 
new human AMPs derived from several proteins (including some proteins involved in 
coagulation cascade, some collagen and mucin isoforms, serum proteins etc.). 
These new hypothetical human AMPs possess an high potential from a 
biotechnological point of view, indeed, being of human origin, likely they will be not 
immunogenic.  
 
1.9 AMPs chemical and biological production methods 
Chemical synthesis and biological production methods are the most popular 
techniques for production of peptides in general and of AMPs in particular. 
Chemical synthesis is particularly well suited when a relatively small amount of 
peptide is required and when the peptide is shorter than about 30 residues [53]. 
However, as the biotechnological application of these molecules cannot overlook 
production costs, biological production methods can be potentially more attractive for 
large scale production. 
Due to the well-known biology, availability of cloning vectors and cheap media for cell 
growth, E. coli is a common microbial platform for AMPs production [54-55]. 
The main concerns in developing an AMP production platform in bacteria expression 
system are: (i) AMP toxicity for the host, ii) intracellular degradation by proteases 
leading to low yields and iii) peptide purification. 
These difficulties can be circumvented by fusing the desired peptides to a carrier 
protein that can protect peptides from proteases, neutralize possible toxic effects and 
provide a convenient route for their purification.  
By now, more than 30 kinds of fusion tags with different sizes and functions have 
been used in AMPs expression. Some examples are: thioredoxin (Trx), glutathione 
S-transferase (GST), maltose binding protein (MBP), intein-mediated systems [56].  
However, also fusion protein strategy has two main drawbacks. Firstly, the fusion 
protein has to be cleaved and peptide needs to be separated from the carrier, 
secondly, the desired peptide usually represents just a small percentage of the 
purified fusion protein. As for the cleavage of the peptide, it can be released from the 
fusion protein by enzymatic or chemical cleavage at a site suitably introduced at the 
carrier-peptide junction [55]. The efficiency and specificity of the cleavage is the main 
bottleneck of fused peptide production. Usually enzymatic proteolysis by factor Xa 
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[57-58], enterokinase [59] and thrombin [60-61], the most used enzymes, is less 
efficient than chemical cleavage [62]. On the other hand, the most popular cleavage 
reagents, like cyanogen bromide (CNBr), formic acid and hydroxylamine, [62], often 
produce unwanted cleavages and side-chain modifications due to the harsh reaction 
conditions needed for the cleavage [62]. 
The thorough characterization of new promising human AMPs requires an effective 
method for their production. For this reason, part of the work of this PhD project has 
been devoted to the development of an efficient and low cost method for the 
production of recombinant AMPs.  
 
1.10 Aims 
The main aims of this research work are: 
I. Development and optimization of efficient strategies for the production 
of recombinant toxic peptides in E.coli.  
II. Production of biologically interesting AMPs selected from the list of new 
potential AMPs suggested by the bioinformatic screening of human 
secreted proteins. 
III. Functional characterization of human AMPs with promising 
pharmacological activities. 
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2.1 Materials  
Expression host strain E.coli BL21(DE3) genotype: 95 F- ompT hsdSB (rB- mB - ) gal 
dcmrne 131 (DE3) and plasmid pET22b(+) were purchased from Novagen (San 
Diego, CA, USA). E. coli strain TOP10F’ was obtained from Invitrogen (San Diego, 
CA, USA). QIAprep spin miniprep kit was from Qiagen (Germantown, MD, USA). 
Wizard SV.Gel and PCR Clean-Up DNA Purification System for elution of DNA 
fragments from agarose gel was purchased from Promega (Madison, WI, USA). 
Enzymes and other reagents for DNA manipulation were from New England Biolabs 
(Ipswich, MA, USA). Ni Sepharose™ 6 Fast Flow was from GE Healthcare (Uppsala, 
Sweden). Difco Nutrient Broth, Mueller Hinton Broth, Tryptic Soy Broth and Yeast 
extract were from Becton-Dickenson (Franklin Lakes, NJ). Trypton was purchased 
from PanReac Applichem (Germany, UE). All other chemicals were from Sigma-
Aldrich (Milano, Italy). 
 
2.2 General procedures 
Bacterial cultures, plasmid purifications and DNA manipulation were carried out 
according to Sambrook [63]. DNA sequences and oligonucleotide synthesis were 
performed by Eurofins MWG Operon service (Ebersberg, Germany). Sodium Dodecyl 
Sulphate PolyAcrylamide Gel Electrophoresis (SDS-PAGE) was carried out 
according to Laemmli [64]. The percentage of polyacrylamide was 6% for the 
stacking gel and 15% in resolving gel (to separate proteins with a molecular weight 
up to 10’000 Da) and 20% to separate peptides (molecular weight lower than 8’000 
Da). Cleavage efficiency was analyzed by SDS-PAGE 20%. Gels were stained by 
Coomassie Blue staining solution containing 4 % (v/v) formaldehyde to cross-link 
proteins and polypeptides [65]. Gallus gallus lysozyme (14.3 kDa), was used as 
molecular marker. When appropriate, the relative amount of bands was determined 
by densitometry performed using the Gel Doc™ XR system (Bio-Rad Laboratories, 
Inc.) equipped with the Quantity One Software. Protein concentration were 
determined using the Bradford Protein Assay (Sigma-Aldrich, St. Louis, MO, USA) 
with standard curves generated using bovine serum albumin. Concentrations of 
purified fusion proteins and peptides were determined by spectrophotometric 
analysis using the extinction coefficients calculated using the ProtParam tool 
(accessible to the address http://web.expasy.org/protparam/). Alternatively, 
Bicinconinic acid Assay was used for peptides without aromatic residues. 
 
2.3 Peptides  
Synthetic GKY20 peptide was from INBIOS s.r.l. (University of Naples, Italy), all other 
synthetic peptides used in this PhD thesis (Apo E(133-150); Apo B(887-911);PA 3(1-25); PA 
3(26-47), βFib(420-447), HHC-36, DJK-6 and IDR-1018) were from Peptide 2.0 Inc 
(Chantilly, USA). Peptides were synthesized using solid-phase 9-fluorenylmethoxy 
carbonyl (Fmoc) chemistry and purified to a purity >95 % using reverse-phase high-
performance liquid chromatography (HPLC). Peptides mass were confirmed by mass 
spectrometry. 
 
2.4 Bacterial growth culture media 
Luria Bertani Broth (LB) contained 1 % (w/v) sodium chloride, 1% (w/v) trypton and 
0.5 % (w/v) yeast extract. The solid medium was obtained from the liquid one by 
adding agar to a final concentration of 1.5% (w/v) as a gelling agent [63]. 
Terrific Broth (TB) was prepared with 1.2 % (w/v) trypton, 2.4 % (w/v) yeast extract; 
0.4 % (v/v) glycerol and potassium phosphate buffer 89 mM pH 7.4. 
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Basal medium 2 (BM2) composed of 62 mM potassium phosphate buffer pH 7.0, 7 
mM (NH4)2SO4, 0.5 mM MgSO4, 10 µM FeSO4 containing 0.4% (w/v) glucose as a 
carbon source. 
 
2.5 Antibiotics 
Ampicillin (Amp) was used always at a concentration of 100 g/mL.  
 
2.6 Construction of the expression vectors 
Synthetic genes coding for recombinant proteins reported in Table 1 in “Results and 
discussion” section were obtained by MWG-Biotech AG (Ebersberg, Germany). All 
codons were optimized for expression in E. coli and restriction sites. 
 
2.7 Expression of recombinant proteins 
E. coli strain BL21(DE3) was used to express recombinant proteins. Cells, 
transformed with pET recombinant plasmids, were grown in 10 mL of TB medium 
containing 100 µg/ml ampicillin, at 37°C up to an absorbance of 2 OD at 600 nm. 
These cultures were used to inoculate 1 L of TB/ampicillin medium supplemented 
with 4 g/L glucose. Cultures were incubated at 37°C up to ODλ600nm  of 3.5-4. 
Expression of recombinant proteins was induced by addition isopropylb- D-
thiogalactopyranoside (IPTG) at a final concentration of 0.4 mM. 
Cells were harvested after overnight induction by centrifugation at 8000x g for 15 min 
at 4°C and washed with 50 mM Tris-HCl buffer, pH 7.4. The bacterial pellet was 
suspended in 50 mM Tris-HCl, pH 7.4, containing 10 mM EDTA, and sonicated in a 
cell disruptor (10 x 1 min cycle, on ice). The suspension was then centrifuged at 
18,000 x g for 60 min at 4°C. Soluble and insoluble fractions were analyzed by SDS-
PAGE. The insoluble fractions containing recombinant protein in the form of inclusion 
bodies, were washed three times in 0.1 M Tris-HCl, pH 7.4, containing 10 mM EDTA, 
2% Triton X-100 and 2 M urea, followed by repeated washes in 0.1 M Tris-HCl, pH 
7.4, to eliminate traces of Triton, urea and EDTA. 
 
2.8 Purification of fusion proteins 
All His6-tagged recombinant proteins reported in Table 1 in “Results and discussion” 
section, were purified by immobilized metal ion affinity chromatography (IMAC), using 
the Ni Sepharose™ 6 Fast Flow resin. 100 mg of fusion proteins were dissolved in 10 
mL of denaturing buffer (6M guanidine/HCl in 50 mM Tris-HCl, pH 7.4) and incubated 
on a rotary shaker at 37°C for 3 h under nitrogen atmosphere. Soluble fractions were 
collected by centrifugation and incubated with 5 mL of Ni Sepharose™ 6 Fast Flow 
resin equilibrated in denaturing buffer. The resin was shaken at 4°C for 16 h and then 
collected by centrifugation. The supernatant, containing the unbound proteins, was 
discarded. The resin was washed three times with 25 ml of denaturing buffer at 4°C 
for 30 min and then packed in a glass column. The fusion proteins were eluted with 
20 ml of 0.1M sodium acetate buffer, pH 5.0, containing 6M guanidine/HCl (elution 
buffer). The eluate was extensively dialyzed against 0.1 M acetic acid at 4°C. 
Samples were stored at -80°C under nitrogen atmosphere. Purified fusion protein 
concentrations were determined by spectrophotometric analysis using the extinction 
coefficients calculated using the ProtParam tool. Before purification ONC-DCless-H6-
(C)GKY20 protein was modified by disulfide bond formation with cysteamine (CEA). 
100 mg of proteins (inclusion bodies) were dissolved in modification and denaturing 
buffer (0.1 M Tris-HCl, pH 8.4, containing 0.5 M cystamine, 10 mM EDTA and 6 M 
guanidine/HCl). After that, soluble fraction was collected by centrifugation and 
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acidified to pH 4.0 by adding glacial acetic acid before to dialyze sample against 0.1 
M acetic acid extensively at 4°C. This step produced a clear protein precipitation. 
Soluble and unsoluble fractions were lyophilized and then dissolved in denaturing 
buffer to purify recombinant protein by IMAC as described above. The modified 
product was named ONC-DCless-H6-(C)GKY20-CEA. 
 
2.9 Acid cleavage of Asp-Pro and Asp-Cys peptide bond 
Routinely acid cleavage of fusion proteins was obtained by using 0.1 M acetic acid at 
pH 2.0 (by addition of 18 mM HCl) with an incubation time of 24 h at 60°C in a water 
bath under nitrogen atmosphere. In the case of ONC-DCless-H6-(C)GKY20-CEA 5 
mM of the reducing agent Tris(2-carboxyethy1)phosphine (TCEP) was added to the 
reaction to remove the cysteamine protecting group. In the case of ONCDCless-H6-
(P)βFib(420-447) and ONC-DCless-H6-(P)βFib(425-447) to prevent methionine oxidation 
TCEP was added at molar ratio TCEP:methionine=5:1. Percentage of cleaved 
protein was determined by densitometric analysis of SDS-PAGE gels as described in 
“General procedures”. 
 
2.10 Purification of recombinant peptides  
After acid cleavage of the fusion proteins, the pH of the mixtures was adjusted to 7–
7.2 by adding NH3. Samples were purged with N2 and incubated at 28°C for 16 h in a 
water bath. Peptides soluble at pH 7 [(P)GKY20, (P)PA3(1-47), (P)βFib(425-447), (P)Apo 
E derived peptides and (P)Apo B derived peptides] were isolated from the insoluble 
carrier through repeated cycles of centrifugation at 18,000 x g for 60 min at 4°C 
(Table 1). Purified peptides were lyophilized and stored at -80°C. Peptide 
concentrations were determined by spectrophotometric analyses using the extinction 
coefficients calculated using the ProtParam tool or by BCA assay. 
Peptides (C)GKY20 and βFib(420-447) that co-precipitated with Onconase carrier at 
neutral pH and (P)PA3 AB(1-47) and its derived peptides [(P)PA 3(1-25)and (P)PA 3(26-
47)] that were present as mixture of peptides after acid cleavage, were purified in RP-
HPLC immediately after acid cleavage (Table 2). 
 
2.11 HPLC  
Peptides purification and purity analysis were performed by reverse-phase 
chromatography. HPLC carried out with a Waters (Milford, MA, USA) system (1525 
binary pump and 2996 photodiode array detector). The column was a C18 (250 x 4,6 
mm, 5µm particle size) Jupiter 5 µm C18 300Å (Phenomenex). The solvents were 
0.05% trifluoracetic acid (TFA) in water (solvent A) and 0.05% TFA in acetonitrile 
(solvent B). Solvent B and TFA were added to the sample before their loading, at a 
final concentration of 5% and 0.1%, respectively. The elution was monitored at the 
wavelength of 280 nm. HPLC gradients are reported in Table 1 and Table 2.  
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Table 1: Peptide purification method after acid cleavage and analysis of purity by RP-HPLC 
(with gradient programs used for each peptides). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide 
 
Peptide purification method after acid 
cleavage 
Analysis of purity  
(HPLC method used) 
Time 
(minutes) 
Solvent 
A 
Solvent 
B 
 
(P)GKY20 
 
Neutralization at pH 7 with NH3 and peptide 
recovery by centrifugation 
 
60’GRAD 
 
5 % 
 
95% 
 
βFib(425-447) 
 
 
Neutralization at pH 7 with NH3  and peptide 
recovery by centrifugation 
 
5’ GRAD 
40’GRAD 
1‘ GRAD 
 
70% 
62% 
5% 
 
30% 
38% 
95% 
 
 
(P)PA 3(1-47) 
 
Neutralization at pH 7 with NH3  and peptide 
recovery by centrifugation 
 
5’ GRAD 
40’GRAD 
1‘ GRAD 
 
80 % 
70% 
5% 
 
20% 
30% 
95% 
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Table 2: Peptide purification after acid cleavage and analysis of purity by RP-HPLC (with 
gradient programs used for each peptides). 
 
 
 
 
 
 
 
 
Peptide 
 
Peptide purification after acid cleavage 
(HPLC method) 
 
 
Analysis of purity  
(HPLC method) 
 
 
 
 
 
 
 
(C)GKY20 
Analytical  Time 
(minutes) 
Solvent 
A 
Solvent 
B Time (min) Solvent A Solvent B 
 
10’ ISO 
5’ GRAD 
40’ GRAD 
1‘ GRAD 
 
90% 
80% 
70% 
5% 
 
10% 
20% 
30% 
95% 
 
 
 
 
 
 
 
60’GRAD 
 
 
 
 
 
 
5 % 
 
 
 
 
 
 
95% Preparative 
Time (min) Solvent A Solvent B 
 
10’ ISO 
5’ GRAD 
60’ GRAD 
60’ ISO 
1‘ GRAD 
 
90% 
80% 
70% 
70% 
2% 
 
10% 
20% 
30% 
30% 
98% 
 
 
 
 
 
 
 
βFib(420-447)  
 
Analytical  
 
 
 
 
 
10’ ISO 
5’ GRAD 
40’GRAD 
1’ GRAD 
 
 
 
 
 
 
95% 
70 % 
62% 
5% 
 
 
 
 
 
 
5% 
30% 
38% 
95% 
Time (min) Solvent A Solvent B 
 
10’ ISO 
5’ GRAD 
40’ GRAD 
1‘ GRAD 
 
95% 
70 % 
62% 
5% 
 
5% 
30% 
38% 
95% 
 
Preparative 
Time (min) Solvent A Solvent B 
 
10’ ISO 
60’ GRAD 
60’ ISO 
1’ GRAD 
 
73% 
70% 
70% 
5% 
 
27% 
30% 
30% 
95% 
 
 
 
(P)PA3AB(1-47) 
and its 
derived 
peptides 
Analytical and preparative  
 
 
10’ ISO 
5’ GRAD 
40’GRAD 
1’ GRAD 
 
 
 
95% 
80 % 
70% 
5% 
 
 
 
5% 
20% 
30% 
95% 
Time (min) Solvent A Solvent B 
 
10’ ISO 
5’ GRAD 
40’ GRAD 
1‘ GRAD 
 
95% 
80 % 
70% 
5% 
 
5% 
20% 
30% 
95% 
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2.12 PyMPO fluorophore conjugation to (C)GKY20 peptide 
Purified (C)GKY20 peptide was conjugate to PyMPO fluorophore for the production 
of a fluorescently labelled peptide. The reaction was carried out as reported in Table 
3 with a molar ratio of 5:5:1 respectively PyMPO:TCEP:thiol groups. Samples were 
incubated at 28°C in a water bath for 16 hours in the dark. Control reaction was 
carried out without adding peptide and TCEP in the reaction mixture. Reaction 
mixtures were analyzed by Reverse phase HPLC equipped with a photodiode array 
detector to determine the UV-Vis spectra of the chromatographic peaks. Solvent B 
and TFA were added to the samples at a final concentration of 5% and 0.1%, 
respectively. The conjugated peptide was purified by the gradient reported in Table 4. 
(C)GKY20-PyMPO peptide was lyophilized, dissolved in 5 mM ammonium acetate 
(AMAC) pH 5.0 and stored at -80°C under nitrogen atmosphere in the dark. Peptide 
concentration was determined by Bradford assay. 
Peptide purity was verified by SDS-PAGE (20%) and RP-HPLC using the gradient 
reported in Table 4. Peptide identity was confirmed by mass spectrometry (MALDI). 
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Table 3: PyMPO fluorophore conjugation to (C)GKY20 peptide 
 
Stock solution 
 
Final concentration 
 
Molar ratio 
 
Tris HCl 1 M pH 7.2 
 
0.1 M  
 
TCEP 
100 mM in water 
1 mM TCEP:-SH 
5:1 
Peptide 1.78 mg/ml (680 µM) 
in AMAC 5 mM pH 5.0 
191 µM 
(0.5 mg/ml) 
 
 
Guanidine-HCl 
(MW 95.53 g mol
-1
) 
 
2 M 
 
 
EDTA 0.5 M pH 8.0 
 
7 mM 
 
 
PyMPO 
100 mM in DMF 
 
1 mM 
PyMPO:-SH 
5:1 
PyMPO:TCEP 
1:1 
Final volume 1 ml  
 
 
 
  Table 4: (C)GKY20-PyMPO purification method and analysis of purity by RP HPLC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide 
Purification method after 
conjugation reaction 
 (HPLC method) 
Analysis of purity  
(HPLC method) 
Time 
(minutes) 
Solvent A Solvent B Time 
(minutes) 
Solvent A Solvent 
B 
 
(C)GKY20-
PyMPO 
 
10’ISO 
5’ GRAD 
30’ GRAD 
10’ GRAD 
1‘ GRAD 
 
 
95% 
80% 
60% 
50% 
5% 
 
5% 
20% 
40% 
50% 
95% 
 
10’ISO 
5’ GRAD 
30’GRAD 
10’GRAD 
1‘ GRAD 
 
95% 
80% 
60% 
50% 
5% 
 
5% 
20% 
40% 
50% 
95% 
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2.13 Antibacterial and antibiofilm assay 
Antibacterial activity assays were carried out by agar dilution plate viable-count 
method ( see accompanying paper and [51] ) and by broth microdilution method to 
determine the Minimal Inhibitory Concentration (MIC) [67]. Routinely assays were 
performed in Nutrient broth 0.5X. HHC-36 peptide was included as positive control in 
the experiment performed during the PhD period abroad. Antibiofilm assay were 
performed by 96-well plate assays and crystal violet staining of adherent biofilms in 
BM2 minimal medium to obtain the Minimal Biofilm Inhibitory Concentrations leading 
to 50% (MBIC50) or 100 % (MBIC100) decrease in biofilm growth as described 
previously [68] using DJK-6 peptide included as positive control. Biofilm cultivation in 
flow cell chambers for the microscopy analysis was performed as described 
previously [68] using P. aeruginosa PAO1 bacterial strain and peptides concentration 
of 10 µg/ml.  
 
2.14 Bacterial strains used for antimicrobial susceptibility test 
Escherichia coli O157:H7, Pseudomonas aeruginosa PAO1, Staphylococcus aureus 
MRSA (clinical isolate C622) and Bacillus subtilis (clinical isolate C626) are clinical 
strains isolated from patients in Vancouver Hospital, Canada. Escherichia coli DH5α, 
Staphylococcus aureus ATCC 6538P were from our laboratory strains collection. 
Pseudomonas aeruginosa PA14 and Pseudomonas aeruginosa KK27 clinical strains 
isolated from cystic fibrosis patients were kindly provided by Dr. Alessandra Bragonzi 
(San Raffaele Hospital, Milan). 
 
2.15 Blood cell isolation and lactate dehydrogenase (LDH) assay  
Venous blood from healthy volunteers was collected in Vacutainer collection tubes 
containing sodium heparin as an anticoagulant (BD Biosciences), in accordance with 
University of British Columbia ethical approval and guidelines. Peripheral blood 
mononuclear cells (PBMCs) were isolated as described [69]. Peptides cytotoxicity 
was verified by LDH assay. Cells (2 x 105) were seeded into 96 well plates (Sarstedt, 
Newton, NC) and incubated at 37°C in 5% CO2 overnight in presence of each 
peptides i.e. Apo E(133-150), ApoB(887-911), PA3(1-25), PA3(26-47), βFib(420-447) or IDR-1018 
(negative control) at concentrations up to 50 µg/ml. The release of cytosolic LDH in 
culture media was then measured using an enzymatic reaction that results in a red 
formazan product which can be measured spectrophotometrically (λ=490 nm). Cells 
treated with a final concentration of 2% Triton X-100 were used as positive control 
demonstrating 100 % of lysis. All experiments were done in triplicate on all blood 
samples used for cell isolation. 
 
2.16 Detection of cytokines/chemokines 
PBM cells were exposed to peptide at concentration of 50 µg/ml; 25 µg/ml and 5 
µg/ml for 24 hours and/or 10 ng/ml of P.aeruginosa PAO1 LPS. IDR-1018 was used 
as positive control peptide. Chemokine MCP-1 and cytokines TNF-α and IL-1β 
secretion in the tissue culture supernatants were detected by sandwich ELISA kits 
(all from eBiosciences) as described [69]. All assays were performed in triplicate 
starting from at least three blood samples.  
 
2.17 MTT assay 
Human monocytic cell line THP-1 were seeded on 96-wells plates (10’000 cells in 
100 μL of RPMI-1640 medium) and grown at 37°C overnight. Peptide (P)PA3(1-47), 
was added at concentrations up to 2-fold MIC value (on E.coli DH5α and S.aureus 
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ATCC6538P). After 24 hours of incubation, 10 μL of a MTT stock solution in PBS 1X 
were added to the cells to a final concentration of 0.5 mg/mL in Dulbecco’s modified 
Eagle’s medium without red phenol (final volume 100 μL). After 4h of incubation, cells 
were harvested by centrifugation at 1500 rpm for 5 minutes, the MTT solution was 
removed and MTT formazan salts were dissolved in 100 µL of 0.1 N HCl in 
anhydrous isopropanol. Cell survival was expressed as the absorbance of blue 
formazan measured at λ=570 nm with an automatic plate reader (Victor 3TM 
Multilabel Counter; Perkin Elmer, Shelton, CA, USA). Experiments were performed in 
triplicate and standard deviations were always <5% for each experiment. 
 
2.18 Ellman assay 
Ellman assay is a colorimetric assay based on Ellman's reagent (5,5'-dithio-bis-[2-
nitrobenzoic acid], DTNB). DTNB reacts with sulfhydryl groups to yield a colored 
(yellow) product, providing a reliable method to measure reduced cysteines and other 
free sulfhydryls in solution. This assay was used to estimate the percentage of free 
thiol cysteine group in ONC-DCless-(C)GKY20 by comparing the sample absorbance 
at λ=412 nm to a standard curve of a sulfhydryl-containing compound such as 
cysteine. 
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3.1 Development of a novel fusion system for recombinant AMPs production 
AMPs are of great interest due to their potential applications in pharmacological and 
food industry. However, commercial uses of bioactive peptides require low cost and 
effective methods for their production. For this reason, part of this work was devoted 
to the development of a novel fusion system for high yield production of recombinant 
peptides in Escherichia coli very well suited for toxic peptides like antimicrobial 
peptides. This section describes briefly the method whereas a detailed description 
can be found in the paper “Rational design of a carrier protein for the recombinant 
production of toxic peptides in Escherichia coli” enclosed at the end of the thesis. 
The denatured form of onconase (ONC), a RNase from Rana pipiens [70], was 
chosen as starting point to design the carrier protein. ONC is a very well suited 
carrier for several reasons: (i) it can be expressed at very high levels in inclusion 
bodies (about 200-250 mg/L in terrific broth); (ii) usually, no soluble ONC can be 
detected in cultures thus minimizing the risk of toxic effects of the ONC-peptide 
fusion proteins; (iii) it is a very small protein (104 aa) thus allowing high yields of the 
peptides after the cleavage; (iv) the solubility of denatured onconase is pH 
dependent – the denatured protein is soluble only at pH <4 – thus allowing the 
purification of peptides soluble at pH 7 by selective precipitation of the carrier.  
Moreover, ONC does not contain Asp-Pro and Asn-Gly sequences and the mutant 
(M23L)-ONC [71] does not contain internal methionine residues, therefore onconase 
carrier will not be cleaved by all common chemical cleavage strategies such as 
formic acid, which cleaves the bond between aspartate and proline, cyanogen 
bromide, which cleaves the Met-X bonds and hydroxylamine, which cleaves the bond 
between asparagine and glycine [72]. 
We tested the efficiency of our strategy by producing GKY20, a short cationic 
antimicrobial peptide derived from the C-terminus of human thrombin [33] active on 
different strains of E. coli with a minimal inhibitory concentration (MIC) lower than 10 
μM. In order to use denatured ONC as carrier for the production of recombinant 
peptide GKY20, (M23L)-ONC cDNA was fused to a linker sequence coding for the 
acid cleavable aspartyl-prolyl sequence, and an in silico designed sequence coding 
for GKY20 (Fig. 1). 
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Figure 1: Schematic representation of expression vectors and recombinant proteins. Fusion 
proteins without (A) and with (B) His6-Tag; C) Amino acid sequence of ONC-(P)GKY20 fusion protein, 
the main cleavage sites are underlined. 
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The synthetic construct and the corresponding recombinant protein were named 
ONC-(P)GKY20 to underline that, by acid cleavage, the recombinant protein releases 
peptide (P)GKY20 i.e. peptide GKY20 with an additional proline at the N-terminus. 
The construct was cloned into pET22b(+) plasmid between NdeI and SacI restriction 
sites (Fig. 1) and expressed into BL21(DE3) E. coli cells.  
SDS-PAGE analysis of induced cultures showed high expression levels of ONC-
(P)GKY20 (200-250 mg/L) as inclusion bodies (Fig.2 in the accompanying paper). 
This sample was used to optimize the acidic cleavage of the DP sequence in order to 
find less harsh cleavage condition than concentrated formic acid (50-75% formic 
acid) at high temperature (from 55 to 80°C ) commonly used in literature [73]. Several 
variables were gradually changed such as acid solution, its concentration, incubation 
temperature, time of incubation and pH, described in accompayning paper. These 
experiments showed that a solution of acetic acid 0.1 M adjusted at pH 1.8-2.0 with 
HCl allows to obtains cleavage efficiencies higher than 90-95%. Unfortunately, they 
also showed that hydrolysis of all the six Asp-X sites present in the sequence of 
(M23L)-ONC occurred (Fig 3 in the accompanying paper), although at different 
degree. Among these sites, two Asp-Cys sites were particularly sensitive to acid 
cleavage (see Fig.1), a result not described in literature. As cleavage efficacy was 
almost comparable to that of the Asp-Pro site this suggested the possibility to 
prepare recombinant peptides with a single additional cysteine at the N-terminus (see 
next section). In addition, some E. coli proteins, present in small amount as 
contaminants in the inclusion bodies, also underwent cleavage, thus releasing short 
fragments and making more complex the purification of (P)GKY20. On the basis of 
these observations we decided to improve the carrier sequence. First, to overcome 
the undesired cleavages observed, all Asp residues were mutated to Glu residues 
and then, to avoid the formation of short fragments, derived from the hydrolysis of 
contaminant E. coli proteins, an His6Tag sequence was added at ONC C-terminus to 
facilitate fusion protein purification and then peptide recovery. Moreover, all cysteine 
residues were mutated to Tyr, Ile or Leu. The choice of the mutations is described in 
detail in the accompanying paper. 
The final carrier protein, ONC-DCless-H6-(P)GKY20, bearing 15 point mutations (see 
Table 1 in the accompanying paper), was produced in the form of inclusion bodies 
with a yield similar or higher than that observed for ONC-(P)GKY20 (Fig. 2 in the 
accompanying paper), thus demonstrating that the amino acid substitutions into the 
carrier sequence did not influence protein expression levels. After purification on Ni-
sepharose, ONC-DCless-H6-(P)GKY20 showed about 98% purity as determined by 
SDS-PAGE densitometry scan (Fig. 6 in the accompanying paper), with a recovery of 
about 95%. After cleavage in 0.1 M acetic acid adjusted at pH 2.0, at 60°C for 24 h, 
SDS-PAGE analysis allowed to estimate 95% efficiency in the release of (P)GKY20 
(Fig. 6 in the accompanying paper). Adjusting the pH to 7.2-7.4 with NH3 and 
incubating the mixture at 28°C for 16 h the uncleaved ONC-DCless-H6-(P)GKY20 
and ONC-DCless-H6 proteins formed macroscopic insoluble aggregates which were 
completely removed by centrifugation (Fig. 6 in the accompanying paper).  
Peptide (P)GKY20 was recovered in the soluble fraction, lyophilized and used for the 
characterization described below without any further purification step. Mass 
spectrometry analysis (Fig. 7A in the accompanying paper), confirmed the peptide 
identity and showed that no modified form (e.g. oxidized or formylated peptides) was 
present in the sample. Final purity of (P)GKY20 peptide, as determined by reverse 
phase chromatography (Fig. 7B in the accompanying paper), typically ranged from 
95% to 99%. The optimized procedure allowed the purification of about 10-11 mg of 
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peptide starting from 100 mg of purified fusion protein with 70-75% recovery 
efficiency (milligrams of purified peptide/expected milligrams of peptide) with respect 
to the theoretical amount of peptide in the fusion protein. 
As the optimized carrier does not possess any methionine residue, cleavage of the 
desired peptides can also be achieved by introducing a methionine residue in linker 
sequence and using CNBr to cleave the Met-X bond. In order to verify this possibility, 
I prepared the fusion protein, ONC-DCless-H6-(PM)GKY20, which contains a Asp-
Pro-Met sequence immediately upstream the GKY20 sequence. By acid hydrolysis it 
releases peptide (PM)GKY20 carrying two additional residues at the N-terminus 
whereas cleaved using CNBr it releases the peptide GKY20 without any additional 
residue at the N-terminus with an efficiency similar to acid cleavage (Fig. 8 in the 
accompanying paper). 
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3.2 Production of GKY20 with a N-terminal cysteine residue 
Even if the sensitivity of Asp-Pro sequences to acid cleavage has been extensively 
reported in literature [73] the efficient acid cleavage of Asp-Cys peptide bonds, to the 
best of our knowledge, has never been described before. Therefore the observation 
that the two Asp-Cys bonds in ONC are very sensitive to acid cleavage suggested 
the intriguing possibility to prepare recombinant peptides with a cysteine residue at 
the N-terminus. Such peptides would possess several useful applications both in 
research and in the biotechnological field. For example, due to the high reactivity of 
the thiol group, cysteine residues can be irreversibly modified –through the use of 
alkylating reagents– and reversibly modified –through the formation of mixed 
disulfides with other thiols. Moreover, being a 1,2-aminothiol, a N-terminal cysteine 
residue can be used in cycloaddition reactions and in protein ligation reactions thus 
significantly expanding the variety of post-synthetic in vitro modifications. 
To explore this possibility, the acid labile Asp-Pro sequence between ONC and 
GKY20 peptide, was replaced with a Asp-Cys sequence thus yielding ONC-DCless-
H6-(C)GKY20 fusion protein in which the only cysteine residue is at the N-terminus of 
the peptide. The high reactivity of thiols however can make complex the purification 
of proteins/peptides with free cysteine residues. In order to prevent any undesired 
irreversible oxidation of the single cysteine residue at the acid cleavage site we 
decided to protect this residue by converting it to a mixed disulfide with cysteamine 
(CEA; 2-aminoethanethiol), a small and very soluble thiol that can be easily removed 
by the addition of any reducing agent (e.g. DTT, β-mercaptoethanol, TCEP ecc.) 
according to a procedure previously developed in our laboratory [70]. Inclusion 
bodies were dissolved in a denaturing buffer containing 0.5 M cystamine (CYA), the 
disulfide of cysteamine. By reacting with free cysteine residues in the proteins CYA 
provides cysteine-cysteamine mixed disulfides and free cysteamine [70]. As the 
reaction is reversible a large excess of cystamine is necessary to modify the majority 
of cysteine residues in the inclusion bodies. After the incubation at 37°C the reaction 
mixture was acidified to pH 4.0 to stop thiol exchange reaction and dialyzed vs 0.1 M 
acetic acid to remove cystamine and denaturants. After dialysis the desired protein 
was found partly in the soluble fraction (about 60%) and partly in the insoluble 
fraction (data not shown). The soluble fraction was lyophilized and both fractions 
were dissolved in denaturant buffer (without reducing or modifying agents). The 
fraction of free thiol groups with respect to the theoretical content of cysteine 
residues in the sample was determined by the Ellman assay.  
The percentage of free cysteine residues was typically below 5% thus demonstrating 
that the protection reaction is efficient. The mixed disulfide-fusion protein, ONC-
DCless-H6-(P)GKY20-CEA, was purified by IMAC as already described for ONC-
DCless-H6-(P)GKY20 fusion protein. The yield of the purification process, was 90-
95%. Sample was dialyzed against 0.1 M acetic acid pH 3, to remove guanidine. Acid 
cleavage was carried out on ONC-DCless-H6-(C)GKY20-CEA modified protein in the 
same conditions (pH 2 and 60°C) previously optimized for (P)GKY20 production.  
The reaction was carried out either in the presence or in the absence of Tris 2-
carboxylethil phosphine (TCEP) a strong reducing agent that, differently from 
conventional reducing agents like DTT, is active also at very acidic pH values. SDS 
PAGE analysis (Fig.2) revealed that TCEP, was essential to obtain an efficient 
cleavage. The cleavage efficiency of ONC-DCless-H6-(C)GKY20-CEA, was of 80%-
85% as determined by densitometric analysis, thus only slightly less efficient than 
that of the Asp-Pro sequence.  
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Even if at the moment the mechanism of the acid promoted cleavage of the Asp-Cys 
peptide bond is not known, it is clear that a free thiol group on cysteine is required. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: SDS-PAGE analysis of chemical cleavage carried out on ONC-DCless-H6-(C)GKY20-
CEA protein at 60°C, pH 2 for 24 h, in the presence or absence of Tris (2-carboxyethy1) 
phosphine (TCEP) reducing agent. Lane 1: Gallus gallus lysozyme (14 kDa, 2 μg); Lane 2: ONC-
DCless-H6-(C)GKY20-CEA in 0.1 M acetic acid; Lane 3: hydrolyzed ONC-DCless-H6-(C)GKY20-CEA 
with TCEP; Lane 4: hydrolyzed ONC-DCless-H6-(C)GKY20-CEA without TCEP. 
 
 
After cleavage of ONC-DCless-H6-(C)GKY20-CEA in the presence of TCEP, in order 
to purify (C)GKY20 peptide, selective precipitation of ONC at neutral pH was 
attempted as described for the purification of the (P)GKY20 peptide. Unexpectedly, 
only 25% of (C)GKY20 peptide was found in the soluble fraction (data not shown). 
To overcome this problem, after chemical cleavage, routinely (C)GKY20 was purified 
by reverse phase HPLC on C18 column (data not shown, ). (C)GKY20 peptide was 
recovered with purity higher than 95% as determined by RP-HPLC (Fig.3). 
Interestingly, purified (C)GKY20 peptide was soluble at concentrations up to 1.7 
mg/ml, thus suggesting that the relevant loss of peptide observed during the 
precipitation step of the ONC carrier could not be due to an intrinsic low solubility of 
(C)GKY20 but rather to the formation of co-precipitates with the ONC carrier.  
Mass spectrometry analysis confirmed the peptide identity and purity (measured 
molecular weight value, 2613.4 Da; 2615 Da expected molecular weight ). (C)GKY20 
peptide final yield was of about 5 mg/L of culture. 
 
 
 
 
 
 
14.3 kDa 
1          2           3          4 
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Figure 3: Reverse phase HPLC analysis on C18 column to verify (C)GKY20 purity. (C)GKY20 
peptide purity was almost 95 %. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
94.8 % purity 
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3.2.1 Selective labelling of (C)GKY20 
Fluorescently labelled proteins and peptides have very wide applications in 
protein/membrane interaction studies, intracellular localization studies etc.. Although, 
lysine and cysteine residues are both common targets of chemical modifications, 
cysteine offers the possibility to perform more selective labelling reaction being less 
frequent in proteins/peptides and more reactive than lysine [74]. Moreover, in the 
specific case of antimicrobial peptides like GKY20, lysine residues are essential for 
their biological activity as they contribute to positive net charge and lipid binding. In 
this context the possibility to prepare recombinant peptides with a single additional 
cysteine residue at the N-terminus appears particularly well suited to the aim of 
preparing labelled AMPs. In order to test this possibility we decided to label peptide 
(C)GKY20 with a commercially available thiol reactive fluorophore. The selected 
fluorophore, 1-[2-(maleimido)etil]-4-[5-(4-metossifenil)-2-ossazolil]piridinio (PyMPO), 
is a relatively small, low polarity and positively charged molecule bearing a maleimide 
moiety which very specifically reacts with thiols under mild conditions (pH 6.5-7.5 at 
37°C). (C)GKY20 peptide was incubated with PyMPO in guanidine 2 M at pH 7, in 
the presence of Tris 2-carboxylethil phosphine (TCEP) as reducing agent in order to 
prevent cysteine oxidation that could reduce modification efficiency. 
Then (C)GKY20-PyMPO was purified by reverse phase HPLC on C18 column. 
Analytical HPLC analysis of labelling reaction mixture (Fig. 4A), showed 9 main 
peaks. The identity of these peaks was deduced from their spectral properties, SDS-
PAGE analysis and by comparison with the HPLC analysis of control reactions 
lacking selected reagents. Peaks 1-4 are likely due to spontaneous 
degradation/hydrolysis of PyMPO. In fact peaks with similar retention times were 
found in a control mixture containing PyMPO but not containing the peptide and 
TCEP(Fig. 4B).  
Peaks 5-7 likely are TCEP-PyMPO adducts. It should be noted that it is known that 
TCEP can react with maleimide groups [75].Peaks 8 and 9, eluted at 39.16 min and 
40.48 min respectively, were identified as the desired (C)GKY20-PyMPO labelled 
peptide, as indicated by the spectroscopic properties ( Fig.4A2 λ max 268 and 405 
nm) and SDS-PAGE analysis (data not shown). 
No peaks were recorded at 37.67 min, the elution time expected for (C)GKY20 
peptide (Fig.5A), thus indicating that (C)GKY20 was completely modified (Fig.4A). 
Preparative RP-HPLC purification was performed using almost the same elution 
gradient with a peptide recovery of about 60%. Peptide was lyophilized and then 
suspended in 5 mM ammonium acetate buffer pH 5. RP-HPLC and SDS-PAGE 
analysis (Fig.5B and 5C respectively), allowed to estimate a peptide purity of about 
99%. Under UV-light (λ=254 nm) the labeled peptide provided a strongly fluorescent 
yellow band in SDS-polyacrylamide gel (Fig. 5C). 
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Figure 4: Reverse phase HPLC analysis on C18 column of (C)GKY20-PYMPO peptide 
modification reaction in the presence of TCEP reducing agent. A) Chromatogram recorded at 280 
nm of (C)GKY20-PyMPO peptide purification, in A1 spectrum of peak 3 and 5 whereas in A2 spectrum 
of peak 8 and 9 B) Chromatogram of PyMPO fluorophore without peptide and TCEP (control reaction). 
In B1 panel, UV absorbance spectrum of (C)GKY20-PyMPO peptide (peak 8). 
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Figure 5: Reverse phase HPLC analysis of purity. A) Chromatogram recorded at 280 nm of 
(C)GKY20 peptide with peak spectrum of absorbance in the small panel B) Chromatogram recorded at 
280 nm of (C)GKY20-PyMPO peptide with peak spectrum of absorbance in the small panel. C) 20% 
SDS-PAGE analysis of purified (C)GKY20 peptide (lane 1 and 3) and purified (C)GKY20-PyMPO 
peptide (lane 2 and 4). On the left gel stained in Coomassie crystal blue, on the right UV-light gel 
image. 
A 
B 
C-GKY20 
C-GKY20-PyMPO 
  1      2        3     4      
C 
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3.3 Antimicrobial activity of thrombin derived peptides 
In order to verify if recombinant peptides (P)GKY20, (C)GKY20, (C)GKY20-PyMPO 
possess antimicrobial activity comparable to that of the synthetic GKY20, all peptides 
were tested by Dr. Zanfardino (Department of Biology, University of Naples Federico 
II), by plate viable-count assay on a Gram-positive strain, Staphylococcus aureus 
ATCC 6538P, and a Gram-negative strain, Pseudomonas aeruginosa KK27 (a 
clinical strain isolated from a cystic fibrosis patient kindly provided by Dr. Alessandra 
Bragonzi, San Raffaele Hospital, Milan).  
Dose-effect curves were carried out testing peptides at final concentrations of 0.1-
0.5-1-2-3 µM. As shown in Fig. 6, (P)GKY20 and (C)GKY20 exhibited the same 
activity displayed by synthetic GKY20 on both strains, thus indicating that the two 
additional residues at the N-terminus did not affect the antimicrobial activity. The 
presence of PyMPO molecule on (C)GKY20, slightly decreased the bactericidal 
activity on both strains. 
Moreover, antibacterial potencies of recombinant (P)GKY20 and synthetic peptide 
GKY20 were further compared by broth microdilution method on several Gram-
positive and Gram-negative strains. Very similar MIC values (Minimal Inhibitory 
Concentration at which no planktonic growth is observed) were found for both 
peptides, (Table 2 in the accompanying paper) thus confirming that an additional 
proline at N-terminus of GKY20 did not affect its activity. 
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Figure 6: Comparison of antimicrobial potency between recombinant peptides and synthetic 
GKY20 by plate viable cell count antimicrobial assay. A) Gram positive strain Staphylococcus 
aureus ATCC 6538P and B) Gram negative strain Pseudomonas aeruginosa clinical isolate KK27. 
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3.4 Expression of further potential human AMPs 
In order to verify the general applicability of our optimized carrier protein ONC-
DCless-H6, several other hypothetical human AMPs (Table 1), were cloned and 
expressed as fusion proteins. All peptides were produced as recombinant peptides 
with an additional proline at the N-terminus and characterized in collaboration with 
the research group of Dr. A. Arciello and Dr. E. Pizzo.  
As described in “Introduction” section 1.8, these peptides were chosen from a pool of 
hypothetical cryptic AMPs derived by analyzing about 4,000 human extracellular 
proteins, through the bioinformatic method developed by Dr. Notomista [52].  
The recombinant fusion proteins, were expressed with yields similar to that of ONC-
DCless-H6-(P)GKY20 (Table 1). Moreover, acid hydrolysis showed cleavage 
efficiency similar or higher than that of ONC-DCless-H6-(P)GKY20 (data not shown). 
Peptides yields ranging from 10 to 30-35 mg/L of culture were obtained, depending 
on the peptide. These results demonstrate that ONCDCless-H6 is well suited to 
produce as inclusion bodies peptides of length up to at least 50 residues.  
The characterization of the biological activities of these novel human AMPs is 
currently ongoing in collaboration with the research groups of Dr. A. Arciello and Dr. 
E. Pizzo. During the activities of the present PhD project I have mainly focused the 
attention on pepsinogen A3 derived peptides [(P)PA 3(1-47) and its fragments] and on 
peptides derived from β-fibrinogen [β Fib(420-447) and β Fib(425-447)], described in details 
in the next sections. 
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Table 1: Peptides produced with ONCDCLess-H6 carrier protein so far. 
 
a
Aminoacid color code: basic residues are colored in blue, hydrophobic residues in green, borderline 
residues in gray, hydrophilic residues in yellow, acidic residues in red. 
b
 Fusion protein yield obtained as mean of at least three independent experiments carried out in a 
shake-flask culture in Terrific Broth medium. 
c 
PA 3(1-25) and PA 3(26-47)
 
were released after chemical cleavage of the full length peptide PA 3(1-47) as 
its own N-terminal and C-terminal peptides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide Primary structure
a
 Fusion protein 
(mg/L of 
culture)
b
 
Apo E(133-150) LRVRLASHLRKLRKRLLR 
 
120 mg/L 
Apo E(133-167) LRVRLASHLRKLRKRLLRDADDLQKRLAVYQAGAR 
 
100 mg/L 
Apo B (887-911) HVALKAGKLKFIIPSPKRPVKLL 
 
145 mg/L 
Apo B (887-925) HVALKAGKLKFIIPSPKRPVKLLSGGNTLHLVSTTK 
 
220 mg/L 
PA 3 (1-47) IMYKVPLIRKKSLRRTLSERGLLKDFLKKHNLNPARKYFPQWKAPTL 
 
200 mg/L 
PA 3(1-25)
C IMYKVPLIRKKSLRRTLSERGLLKD 
 
-
c
 
PA 3(26-47)
C FLKKHNLNPARKYFPQWKAPTL -
c
 
α Fib (805-831) GVVWVSFRGADYSLRAVRMKIRPLVTQ 
 
150 mg/L 
β Fib (420-447) 
 
GVVWMNWKGSWYSMRKMSMKIRPFFPQQ 
 
150 mg/L 
β Fib (425-447) NWKGSWYSMRKMSMKIRPFFPQQ 150 mg/L 
γFib (366-395) GIIWATWKTRWYSMKKTTMKIIPFNRLTIG 
 
150 mg/L 
h11 Beta (235-261) GVFYPWRFRLLCLLRRWLPRPRAWFIR 
 
200 mg/L 
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3.5 Purification of recombinant pepsinogen A-3 derived peptides  
Through the bioinformatic method [52] three fragments of human pepsinogen A3 
were predicted to be endowed with antibacterial activity: PA 3(1-47) corresponding to 
the activation peptide of human pepsin, and its N- and C- terminal portions here 
named, PA 3(1-25) and PA 3(26-47) respectively. 
The two shorter peptides, 25 and 22 residues long, were also included in the panel of 
five peptides produced by chemical synthesis (see section 3.7 “Functional 
characterization of potential new human AMPs”) whereas PA 3(1-47), 47 amino acids 
long, was prepared only as recombinant peptide. 
Peptide PA 3(1-47) is the activation peptide of human pepsin A3. In vivo, at neutral pH 
in the gastric mucosa of vertebrates, the precursor form of pepsin A-3 is synthesized 
and folded as a zymogen, pepsinogen A-3 (UniProtKB ID: P0DJD8). Maturation of 
pepsinogen, through the proteolytic cleavage release of the first 47 residues under 
acidic conditions, yields active pepsin A-3. [76]. 
Activation peptides of pepsinogen isoforms inhibit the proteolytic activity of pepsins 
by blocking the catalytic site thus allowing safe storage and secretion of the protein  
[76]. To the best of our knowledge, no other significant function has been attributed 
to activation peptides of pepsin. However it has been reported that the propeptide of 
pepsin isoform C from Rana catesbeiana shows antimicrobial activity against several 
microorganisms [77].  
An in silico designed DNA fragment coding for PA 3(1-47) was cloned and successfully 
expressed by using ONCDCLess-H6 as carrier protein (Fig.7A) as previously 
described for the production of (P)GKY20 peptide. The corresponding recombinant 
peptide named (P)PA3(1-47) for the additional proline at its N-terminus (48 amino 
acids) was produced with yield even higher than that of (P)GKY20, i.e. 30-35 mg/L of 
Terrific Broth. Moreover, final purity of (P)PA3(1-47), determined by RP-HPLC, typically 
was about 95% (Fig. 7B). 
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Figure 7:Purification of the recombinant activation peptide of human pepsinogen A3. 
A) 20 % SDS-PAGE analysis. Lane 1: Gallus gallus lysozyme; Lane 2: ONC-DCless-H6-(P)PA 3(1-47) 
purified in acetic acid 0.1 M; Lane 3: Acid cleavage of ONC-DCless-H6-(P)PA 3(1-47) fusion protein; 
Lane 4 and 5: Soluble fraction after neutralization at pH 7 (5 µg and 10 µg peptide respectively); Lane 
6: Insoluble fraction after neutralization at pH 7 (carrier protein and uncleaved fusion protein). 
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By SDS-PAGE analysis, RP-HPLC (Fig.7), and mass spectrometry (data not shown) 
we detected two peptides derived from the acid cleavage of the internal DF sequence 
(cleaved with an efficiency of about 5%). These peptides correspond to the N-
terminal 26 residues [(P)IMYKVPLIRKKSLRRTLSERGLLKD] and to C-terminal 22 
residues [FLKKHNLNPARKYFPQWKAPTL] of (P)PA 3(1-47).  
In order to characterize these two smaller peptides, we prepared a variant of (P)PA 
3(1-47) in which, a proline residue is inserted between Asp 25 and Phe 26 to improve 
cleavage efficiency. This fusion protein called ONCDCLess-H6-(P)PA 3 AB(1-47) by 
acid cleavage yielded peptides (P)PA 3(1-25) (26 aa) and (P)PA 3(26-47) (23 aa). (Fig. 
8A). The cleavage efficiency of internal DP was about 85% as determined by 
densitometric analyses. Peptides were purified by RP-HPLC (Fig. 8B), with a 
recovery of 80%. Peptides identity was confirmed by mass spectrometry with a 
measured molecular weight corresponding to that of the theoretical value i.e. (P)PA 
3(1-25) of 3111.8 Da and (P)PA 3(26-47) of 2795.3 Da as determined by using Protparam 
tool. 
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Figure 8: Purification of the recombinant peptides derived from activation peptide of human 
pepsinogen A3. A) 20 % SDS-PAGE analysis. Lane 1: Gallus gallus lysozyme; Lane 2: cell lysate 
0.126 O.D; Lane 3: Inclusion bodies after Triton/urea wash 0.126 O.D. Lane 4: Soluble fraction 0.126 
O.D.; Lane 5: ONC-DCless-H6-(P)PA3 AB(1-47) purified by IMAC; Lane 6: purified ONC-DCless-H6-
(P)PA3 AB(1-47) in acetic acid 0.1 M; Lane 7: Acid cleavage of ONC-DCless-H6-(P)PA3 AB(1-47) fusion 
protein; Lane 8: Soluble fraction after neutralization at pH 7; Lane 9: Carrier protein at ph 7.  
B) Reverse phase HPLC chromatogram of acid cleavage mixture. Peak 1: (P)PA 3(1-25) peptide; Peak 
2: (P)PA 3(26-47) peptide; Peak 3: (P)PA 3 AB(1-47) peptide.  
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3.5.1 Antimicrobial activity 
The antibacterial properties of the peptides derived from pepsinogen A3 were studied 
by viable count assay on plate and by the broth microdilution method for the 
determination of MIC values. Viable count assay were performed on Gram-negative 
strain Escherichia coli DH5α and on Gram-positive strain Staphylococcus aureus 
ATCC6538P at concentration of 1 µM for each peptide. (P)PA 3(1-47) peptide showed 
similar activity on both strains (Fig. 9) whereas its fragments were both more 
effective on Escherichia coli DH5α. Interestingly, by using equimolar concentrations 
of both fragments, on Escherichia coli, the percentage of survived cells was very 
similar to that measured using (P)PA 3(1-47) and lower than that expected for a purely 
additive effect. This suggests a cooperation between the two halves of (P)PA 3(1-47). 
 
 
 
Figure 9: Comparison of antimicrobial potency between recombinant pepsinogen A 3 derived 
peptides by plate viable cell count antimicrobial assay treating cells with 1 µM of each peptide. 
 
 
Furthermore, MIC values were determined on pepsinogen A3 recombinant peptides, 
using (P)GKY20 as positive control and antibiotic polymyxin B and vancomycin 
effective against most Gram negative and Gram positive bacteria, respectively. As 
shown in Table 2, full length (P)PA 3(1-47) was active against all bacteria strains 
tested, including Pseudomonas aeruginosa PA14, a pathogenic antibiotic-resistant 
strain, with a MIC value of 5.5 µM.  
As its synthetic counterpart (see section 3.7.1 Table 5), recombinant (P)PA 3(26-47) did 
not inhibit planktonic growth at the concentrations used, whereas the N-terminal 
peptide (P)PA 3(1-25) showed a potency similar to the full-length peptide, within 
micromolar range concentration (Table 2). Taken together, these data demonstrated 
that all three peptides are endowed with antibacterial activity as predicted. 
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Table 2: Antibacterial acitivity of pepsinogen A3 derived peptides by broth microdiluition broth 
assay and (P)GKY20 peptide (positive control). MIC value average of three independent 
experiments carried out in Nutrient Broth 0.5X. 
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In addition, treatment with full length (P)PA 3(1-47) up to 2 fold MIC value had no toxic 
effect on THP1 human monocyte cells viability after 24 hours of incubation (Fig. 10). 
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Figure 10: Dose response effect of full length (P)PA 3(1-47) peptide on THP-1 human monocyte 
cells after 24 h of incubation (MTT assay). 
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3.6 Purification of recombinant β Fibrinogen derived peptides  
Fibrinogen is a glycoprotein consisting of three pairs of polypeptide chains, α, β and 
γ, symmetrically interconnected through multiple disulfide bonds. Fibrinogen in 
plasma is heterogenous, being present as different forms characterized by different 
molecular weight, solubility and ability to form fibrin clot. This latter fibrinogen feature, 
constitutes its main physiological function. Indeed, through cleavage by thrombin and 
release of the fibrinopeptides A and B, is converted to fibrin in the last step of the 
coagulation process [78]. 
Relatively recent studies show that blood coagulation and inflammation are intimately 
connected and co-operate in the early response to infection [79]. Fibrinogen is a key 
player in acute phase response to trauma, wounds, bacterial infections, moreover it 
is also known to have pro-inflammatory properties.  
In fact, recently, Pahlman et. al have demonstrated that thrombin-treated fibrinogen 
directly kills bacteria. They also reported that peptide fragment GHR28 released from 
the β chain of fibrinogen has broad antibacterial activity [47]. This is not completely 
surprising, taking into account that proteins homologous to fibrinogen-related are 
common also among invertebrates where they are not involved in coagulation but in 
immune defense reactions [80]. 
Very interestingly our bioinformatic method predicted the presence of a putative AMP 
at the C-termini of each chain of human fibrinogen (see Table 1). 
For sake of brevity, only the production and characterization of the β fibrinogen 
derived peptide will be discussed in this thesis. 
As described for thrombin and pepsinogen derived peptides we used ONC-DCless-
H6 to prepare recombinant peptide (P)βFib(420-447).  
Chemical cleavage efficiency of ONCDCLess-H6-(P)βFib(420-447) fusion protein was 
even higher than that observed for the previous peptides ( ≥98 %). However, after 
neutralization of the acids present in the cleavage buffer we found that peptide 
(P)βFib(420-447), was present essentially in the insoluble fraction with the ONC carrier. 
As the carrier protein ONCDCLess-H6, after cleavage, retains the His6 tag we 
attempted to separate ONC-DCless-H6 and (P)βFib(420-447) by IMAC under denaturing 
condition to avoid precipitation of carrier and peptide. Unfortunately even if peptide 
was recovered with an efficiency over 70%, a significant amount of the carrier protein 
(about 20%) was still present in sample ( data not shown).  
For this reason, I chose to purify directly by RP-HPLC the acidic cleavage mixture 
containing ONC-DCless-H6 and (P)βFib(420-447) (Fig. 11). In this case peptide recovery 
was about 50% but the final peptide purity was 96% as determined by RP-HPLC 
(Fig.12). 
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Figure 11 : Purification of the recombinant fibrinogen derived peptide βFib(420-447). 
A) Purification of acidic cleavage mixture of (P) βFib(420-447) peptide performed by C18 RP-HPLC. 
B) 20 % SDS-PAGE analysis for peak assignment. Lane 1: peak 1; Lane 2: peak 2 purified (P)βFib(420-
447 (1); Lane 3: peak 3 purified (P)βFib(420-447) (2); Lane 4: Gallus gallus lysozyme; Lane 5: peak 4 
purified cleaved fusion protein ONC-DCless-H6; Lane 6: purified uncleaved fusion protein ONC-
DCless-H6-(P)βFib(420-447). 
 
 
 
 
1 
2 
4 
5 
(P)βFib(420-447) (1) 
(P)βFib(420-447) (2) 
ONC-DCless-H6-(P)βFib(420-447) 
ONC-DCless-H6 
3 
A 
B 
ONC-DCless-H6-(P)βFib
(420-447)
 
ONC-DCless-H6 
(P)βFib(420-447) 
1          2         3            4            5         6 
 52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Analysis of purity of (P)βfib(420-447) by reverse phase HPLC chromatogram recorded 
at 280 nm. 
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The yield of the recombinant peptide (P)βFib(420-447), was about 10 mg/L of Terrific 
Broth, hence similar than that of the peptide previously described (P)GKY20.  
It is interesting to note, that (P)βFib(420-447), was soluble in ammonium acetate 5 mM 
pH 5 and in water up to a concentration of 1 mg/ml. Higher concentrations lead to 
aggregates formation. A similar behavior was also observed for the corresponding 
synthetic peptide described in section 3.7. 
These findings prompted us to analyze more accurately the sequence of βFib(420-447). 
We noticed that the N-terminus of this peptide contains four adjacent hydrophobic 
residue starting from residue 2: GVVWMNWKGSWYSMRKMSMKIRPFFPQQ. 
Moreover, “TANGO”, a server for automatic prediction of amyloidogenic regions in 
proteins (http://tango.crg.es/), confirmed that this hydrophobic sequence has a high 
propensity to form beta-aggregates. 
Even if, without these four residues, the predicted antimicrobial potency of the 
peptide slightly decreases we decided to prepare a peptide five residues shorter, 
βFib(425-447). The coding sequence for βFib(425-447) was fused to ONC-DCless-H6 
cDNA and expressed in E.coli (Fig.13) .  
The solubility of (P)βFib(425-447) proved to be significantly higher that of (P)βFib(420-447), 
(at least up to 2 mg/ml in ammonium acetate at pH 5 or in water). This allowed to 
purify (P)βFib(425-447) by selective precipitation of carrier protein at pH 7 (Fig. 13), as 
described for (P)PA 3(1-47) and (P)GKY20. 
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Figure 13: Purification process of (P)βFib(425-447). SDS PAGE analysis. Lane 1: Gallus gallus 
lysozyme and (P)GKY20 peptide; Lane 2: cell lysate of induced culture 0.126 O.D.; Lane 3: soluble 
fraction after cell lysis 0.126 O.D; Lane 4: insoluble fraction after cell lysis 0.126 O.D; Lane 5: purified 
ONC-DCless-H6-(P)βFib(425-447) recombinant protein after dialysis against 0.1 M acetic acid; Lane 6: 
acid cleavage of ONC-DCless-H6-(P)βFib(425-447). Lane 7: Soluble fraction after neutralization of the 
cleavage reaction [(P)βFib(425-447) peptide]; Lane 8: molecular weight marker Color Burst (220 -8 kDa); 
Lane 9: Insoluble fraction after neutralization of the cleavage reaction [cleaved and uncleaved ONC-
DCless-H6-(P)βFib(425-447) recombinant protein]. 
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3.6.1. Antimicrobial activity  
Dose effect curve by viable count assay was performed on Gram-positive strain 
Staphylococcus aureus ATCC6538P in order to verify the antibacterial properties of 
the fibrinogen derived peptide. (P)βFib(420-447) was effective on this strain reducing to 
40% cell survival at concentration of 3 µM (Fig.14). 
 
 
 
 
Figure 14: Antimicrobial potency of (P)βFib(420-447) peptide by plate viable cell count assay. 
compared to (P)GKY20 peptide, used as positive control. 
 
 
 
MIC values were determined on three bacterial strains (E. coli DH5α, P. aeruginosa 
PA14 and S. aureus ATCC6538P) by broth microdilution method using (P)GKY20 as 
control peptide. Peptides showed antibacterial activity on all strains at concentration 
similar to that of (P)GKY20 peptide (Table 3). Interestingly, both β fibrinogen derived 
peptides, possess the same potency.  
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Table 3: Antimicrobial activity of recombinant β fibrinogen derived peptide and (P)GKY20 
(positive control) by broth microdilution broth. MIC value average of three independent 
experiments carried out in Nutrient Broth 0.5X.  
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3.7 Functional characterization of potential new human AMPs  
Among our wide panel of novel AMPs, five particularly promising peptides - Apo B(887-
911), Apo E(133-150), βFib(420-447), and the two fragments of pepsinogen activation 
peptide (Table 1) - were prepared by chemical synthesis and characterized in the 
laboratory of prof. Robert Hancock (University of British Columbia, Vancouver, 
Canada) whose research group has extensive experience in the field of the 
characterization of AMPs. 
Three types of biological activities were investigated: (i) antimicrobial activity; (ii) 
antibiofilm activity; (iii) immunomodulatory activity. 
 
3.7.1.Antimicrobial activity 
The five selected peptides were assayed on a panel of representative Gram-negative 
and Gram-positive bacteria: Pseudomonas aeruginosa strain PAO1 and clinical 
isolates of Escherichia coli O157:H7, methicillin-resistant Staphylococcus aureus 
(MRSA; clinical isolate C622) and Bacillus subtilis (clinical isolate C626). Minimal 
Inhibitory Concentration values (MIC100), i.e. the minimal concentration that inhibits 
completely the bacterial planktonic growth, were determined by the broth 
microdilution method as described by Hancock et al. [67]. 
Three controls were included in assays: peptide HHC-36, a synthetic peptide whose 
antimicrobial activity has already been demonstrated [81], polimixyn B, a natural 
antibiotic peptide active only on Gram-negative bacteria and vancomicyn, an 
antibiotic active only on Gram-positive bacteria. 
MIC assays were initially performed in Mueller Hinton Broth, an extremely rich 
medium, frequently used in the determination of antimicrobial activity. All MIC values 
measured in this medium were very high (Table 4). Moreover, some peptides 
(especially the β-Fibrinogen derived peptide) showed a significant tendency to form 
aggregates in Mueller Hinton Broth (MHB) as evidenced by turbidity. Since it has 
been demonstrated that very rich media can influence MIC values of peptides, I 
repeated the assay in different media. The lowest MIC values were obtained in 
Nutrient Broth and in 50% Nutrient Broth (Table 5). 
With the exception of PA 3(26-47) all the peptides showed antimicrobial activity but with 
significant differences from strain to strain. Apo E(133-150) was particularly active on P. 
aeruginosa and S. aureus with MIC values similar to those of the control peptide 
HHC-36. Apo B(887-911) and PA 3(1-25) were active only on E. coli and S. aureus, 
respectively. βFib(420-447) was active on B. subtilis and S. aureus. 
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Table 4: Antibacterial activity of five human peptides and HHC36 ( positive control) by broth 
microdiluition broth. MIC value average of three independent experiments carried out in Mueller 
Hinton Broth. Antibiotics were used as control. 
 
 
 
 
 
 
 
Table 5: Antibacterial activity of five human peptides and HHC36 ( positive control) by broth 
microdiluition broth. MIC value average of three independent experiments carried out in Nutrient 
Broth 0.5X. Antibiotics were used as control. 
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3.7.2 Antibiofilm activity 
As mentioned in the Introduction, biofilm is involved in more than 80% of infections. 
Moreover, antibiotics often are ineffective against biofilm. For this reason I decided to 
investigate the ability of human peptides to eradicate biofilm formed by the same 
Gram negative and Gram positive clinical isolates used for the antibacterial activity 
assay. This allowed to perform a comparison between antimicrobial and anti-biofilm 
activity on each selected strain. 
Preliminarily to the anti-biofilm assays, I studied the conditions (in particular the 
broth) inducing the sessile phenotype in the selected strains. The best medium 
favouring biofilm growth of both Gram-negative bacteria was BM2 minimal broth (Fig. 
15A). Unfortunately, in the case of Gram positive bacteria, even if several growth 
conditions were tested, no satisfactory biofilm growth was obtained, therefore 
antibiofilm assays were not performed on these two strains (Fig. 15B) . 
 
 
 
 
 
 
 
 
 
Figure 15: Selection of the best biofilm growth medium. A) Biofilm growth of Gram-negative 
bacteria. B) Biofilm growth of Gram-positive bacteria (clinical isolate strains). 
A 
B 
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The antibiofilm assay was performed following the protocol described in Materials 
and Methods [68]. The Minimal Biofilm Inhibitory concentration, MBIC, is the 
concentration required to fully prevent biofilm formation (MBIC100) or to reduce to 
50% biofilm growth (MBIC50). Also in this case three controls were used: the D-
peptide DJK-6, a very effective synthetic antibiofilm peptide [82], and the antibiotics 
polymyxin B and vancomycin. 
Among the five human peptides, Apo E(133-150) and βFib(420-447) exhibited a good 
antibiofilm activity in MBIC assay. In particular, ApoE(133-150) completely inhibited 
biofilm growth of both Gram-negative bacteria at concentrations similar to those 
required to inhibit planktonic growth (Table 6). 
βFib(420-447) peptide showed an antibiofim activity specific for E.coli (MBIC100 is 64 
µg/ml i.e. about 18 µM, Table 6). 
Interestingly, peptide Apo B(887-911), was able to reduce at 50% biofilm growth of 
P.aeruginosa (MBIC50 is 8-16 µg/ml, Table 6) at concentrations that had no effect on 
planktonic growth (MIC on P. aeruginosa is >256 µg/ml, Table 5). This behavior is not 
completely surprising. Indeed, in literature there are recent evidences that other 
peptides, like for example IDR-1018, inhibits biofilm growth at concentrations lower 
than those required to inhibit planktonic growth [83] thus suggesting that antimicrobial 
and anti-biofilm activity could depend on different mechanisms. 
 
 
 
 
 
Table 6: Antibiofilm activity of five human peptide and DJK-6 peptide ( positive control) by 
crystal violet stained 96 multiwell assay. MBIC value average of three independent experiments 
carried out in BM2 medium. Antibiotics were used as control. 
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A deeper characterization was performed in the case of peptides Apo B(887-911), PA 
3(1-25) and PA 3(26-47) through experiments of biofilm eradication in a flow cell 
chamber. Such method allows to monitor morphological alterations of the biofilm 
even when a MBIC100 value cannot be measured. Biofilm was allowed to develop for 
three days in flow cell chambers with a constant flow of BM2 minimal medium. 
Peptides were added to the flow medium during the entire three days of the 
experiment, then the resulting surface-adherent cells and biofilm were stained with 
stains that evidence total cells ( green fluorescent dye Syto-9) or with stains selective 
for dead cells (red fluorescent dye propidium iodide) and visualized using confocal 
laser scanning microscopy [68]. As shown in Fig. 16A, treatment with 10 µg/ml of 
ApoB(887-911) led to a significantly decreased biofilm thickness, and triggered some cell 
death, as indicated by red dots. These data, confirmed that the MBIC50 value on P. 
aeruginosa for ApoB (887-911) is in the range 8-16 µg/ml corresponding to 3 - 6 µM. 
Interestingly, also biofilm treated with PA 3(26-47) peptide showed a morphological 
alteration in terms of reducing biofilm thickness at concentration of 10 µg/ml (about 4 
µM) (Fig. 16B), i.e. a concentration much more lower than MIC value toward 
planktonic PAO1 cells (MIC on PAO1 ≥ 256 µg/ml corresponding to about 95 µM, see 
Table 5). Finally, cells treated with PA 3(1-25), did not show significant biofilm 
reduction (Fig. 16C).  
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Figure 16: Biofilm eradication in flow cell system and microscopy. A) Treatment with Apo B(887-
911) decreases biofilm thickness and triggers death of some cells, confirming that the MBIC50  value on 
P.aeruginosa for Apo B(887-911) is about 8-16 µg/ml. B)The biofilm reduction of PA 3(26-47) is at 
concentration much lower than MIC value.C) Treatment with 10 µg/ml of PA 3(1-25) was not sufficient to 
significative alter biofilm structure. 
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3.7.3 Immunomodulatory activity and ability to enhance the innate immune 
system 
In response to microbial invasion, immune cells release a complex network of 
cytokines to fight infection. It is the net effect of interactions between pro-
inflammatory and anti-inflammatory molecules over time that determines the nature 
of the immune response in individual patients [23]. Host defense peptides can 
modulate this immune response. However, it should be reminded that, there is a 
huge variability of the immune response between individuals, therefore 
immunological studies to be significant should be conducted on a suited number of 
subjects.  
The immunomodulatory properties I investigated included: 
i) Immunomodulatory activity (suppression of potentially harmful excessive 
inflammatory response triggered by “microbial signature molecules” like 
lipopolysaccharides from Gram negative strains); 
ii) Enhancement of innate immune response (by induction of chemokines 
involved in leukocyte activation). 
 
i) Immunomodulatory activity 
In vitro preliminary experiments were performed isolating peripheral blood 
mononuclear cells (PBMCs) from healthy blood adult volunteers. A PBMC is defined 
as any blood cell with a round nucleus (i.e. a lymphocyte, a monocyte, or a 
macrophage). They are a critical component of the immune system. 
Preliminary to the immunomodulatory assay, the cytotoxic effect of all peptides was 
investigated using the lactate dehydrogenase (LDH) assay. As AMPs usually act via 
cell membrane damaging, this is a particularly well suited colorimetric assay to 
quantitatively measure lactate dehydrogenase (LDH) released into the media from 
damaged cells as a biomarker for cellular cytotoxicity and cytolysis.  
Even at the highest concentration tested for each peptide (50 µg/ml), the release of 
the cytosolic enzyme, LDH, was lower than 5% compared to cells treated with 0.2% 
triton X100, indicating that none of the selected peptides tested possesses lytic 
activity (Fig. 17). 
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Figure 17: Cytolysis effect of the five studied human peptides on human PBMCs. Colorimetric 
assay based on the cytosolic enzyme activity LDH. 
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To investigate the immunomodulatory properties of human peptides, PBMCs were 
stimulated with P. aeruginosa LPS and treated with three different concentrations of 
each peptide (5-25-50 µg/ml). The immunomodulatory peptide IDR-1018, a synthetic 
versions of natural host defense peptides, was included as a positive control. Levels 
of two main proinflammatory cytokines, tumor necrosis factor–α (TNF-α) and 
interleuchin 1-β (IL-1β), were measured by ELISA. 
Data collected by using PBMCs from three independent donors (Fig.18) showed that 
in response to LPS high levels of TNF-α were released from untreated cells whereas 
a general significant reduction of this pro-inflammatory cytokine was observed in cells 
treated with most of the peptides tested at the lowest concentration (Fig.18A). This 
indicates that most of the peptide tested possess immunomodulatory properties 
being able to suppress LPS-mediated inflammation. Indeed, treating PBMCs with 
increasing doses of peptides after LPS stimulation, the overall TNF-α reducing trend 
was confirmed for most peptides. Interestingly, dose-dependent response was mostly 
evident with ApoB(887-911) whereas an opposite trend with PA 3(1-25) was observed, 
(Fig.18B). This behavior, is not completely surprising, since some peptides, like 
hβDF2, can act as alarmins i.e. with a pro-inflammatory trend, some others act by 
TNF-α reduction, like LL-37 [30].  
On the other hand, no significant cytokine IL-1β reduction was observed on PBM 
cells, in response to LPS mediated inflammatory stimulation and treatment with each 
peptide (data not shown). 
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Figure 18: TNF-α reduction mediated by human peptides on PBMCs cells. A) Percentage 
reduction of TNF-α after stimulation with 20 ng/µl of Pseudomonas aeruginosa PAO1 LPS and 
treatment with the lowest peptide concentration 5 µg/ml. B) Dose response effect on LPS stimulated 
TNF- α concentration release after treatment with crescent doses (5-25-50) µg/ml of human peptides. 
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ii) Enhancement of innate immune response 
As HDPs promote bacterial clearance by acting on the host immune response 
specifically enhancing the production of chemokines, I investigated the ability of 
human peptides to induce the release of MCP-1, monocyte chemotactic protein-1, a 
member of CC chemokynes subfamily mainly involved in the activation of leukocyte 
migration. 
Data obtained using PBMCs of five independent donors (Fig.19) showed that in the 
absence of LPS-stimulation, PBMCs produce basal level of MCP-1 (about 1000 
pg/ml). In response to LPS the release of MCP-1 is greatly enhanced (5000-20000 
pg/ml).  
Almost all human peptides increased levels of MCP-1 secretion compared to 
untreated cells (control). Apo E(133-150) showed a stimulating ability similar to that of 
the control peptide IDR-1018 (about 10000 pg/ml and 8000 pg/ml respectively) and 
with a dose dependent trend. Interestingly βFib(420-447) showed the highest stimulation 
activity comparable to that of LPS (about 22000 pg/ml but with a great variability from 
donor to donor). PA 3(1-25) increases MCP-1 release in a dose dependent manner. 
Thus, at least three of the selected peptides possess interesting immunomodulatory 
activity. 
Overall, the analysis performed in the host laboratory indicate that the five potential 
AMPs, identified by the bioinformatic approach, show typical features of host defense 
(antimicrobial) peptides. 
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Figure 19: Induction of MCP-1 release on PBMCs treated with five human peptides compared to 
IDR-1018 ( control peptide). 
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Infections attributed to multi-drug resistant (MDR) microbes, are increasingly 
frequent. Therefore a huge effort to improve or develop molecules that can inhibit 
pathogens without incurring in pathogen resistance is urgently required. In this 
context, antimicrobial peptides (AMPs) are particularly well suited candidates being 
the most ancient weapon of innate immunity. In addition to their antimicrobial action, 
several AMPs show additional biologic properties usually correlated to the control of 
infections, a feature that makes them attractive therapeutic agents.  
It is tempting to speculate that human proteome is a yet unexplored source of 
bioactive peptides with many potential pharmacological applications. In fact, a wide 
variety of human proteins whose primary functions are not necessarily related to host 
defence, contain AMPs hidden inside their sequence.  
The activities of the present PhD thesis are framed in the context of a more complex 
research project whose main goal is the development of human AMPs-based 
antimicrobial drugs for topic applications like treatment of surgical wounds, of ulcers 
and of skin, mouth and airways infections. Being human peptides, their use will limit 
the risk of inducing immune response.  
Preliminarily to the activities of the present PhD work, our research group has 
developed an in silico screening method that allows to localize antimicrobial regions 
hidden inside the primary structure of precursors, developed by Dr. Notomista. Using 
this method to screen about 4’000 human extracellular proteins, a wide list of 
potential new AMPs was obtained. These findings represented the starting point. The 
main aim of the present PhD project was to select and characterize the most 
pharmacologically interesting molecules suggested by the bioinformatic screening, in 
order to find candidates suited for the development of novel antimicrobial and anti-
inflammatory agents. In line with this goal, the main tasks carried out were: 
I. Development and optimization of efficient strategies for the production 
of recombinant toxic peptides in E.coli.  
II. Production of biologically interesting AMPs selected from the in silico-
defined list of potential AMPs. 
III. Functional characterization of the new AMPs to find promising 
pharmacological activities. 
 
Through a rational design strategy the suitability of onconase (ONC) as a carrier for 
the production of recombinant peptides in E. coli was progressively improved. The 
final version of the protein, ONC-DCless-H6, is a very efficient carrier particularly 
suited for the production of peptides potentially toxic for the host E. coli. It is 
expressed at high levels (>200 mg/L) efficiently forming inclusion bodies. Chemical 
cleavage of the fusion protein can be performed in diluted acids without the need to 
employ high concentrations of formic acid that is often chosen for its 
denaturing/solubilizing properties. After the cleavage at acidic pH, the ONC moiety, 
ONC-DCless-H6, can be easily removed due to its insolubility at neutral pH providing 
an easy procedure for peptide purification. Moreover, our strategy also allows to 
prepare peptides with a N-terminal cysteine residue that could find many applications 
in research and biotechnological procedure like for example preparation of labeled 
peptide, protein ligation in the semi-synthesis of modified proteins, immobilization on 
support etc. It should be noted that even if our method was developed specifically to 
prepare peptides toxic for the host it can be used for the production of other peptides. 
In particular, due to its simplicity and limited costs, this fusion system can be applied 
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to medium/large scale production of peptides with pharmacological activity required 
for example in the clinical trial phases. It is worth to underline that our method is 
complementary to chemical synthesis being particularly well suited to prepare 
peptide longer than 20-25 residues. 
Using ONCDCless-H6 carrier protein several potential human AMPs, from 20 to 
almost 50 amino acids were successfully produced. All these peptides showed as 
expected antimicrobial activity thus validating the efficacy of the bioinformatic 
screening method. 
In addition some of these peptides have been analyzed for their anti-inflammatory 
and immuno-modulating activity. Apo E(133-150) showed broad spectrum of activity on 
both Gram-negative and Gram-positive bacteria but also anti-biofilm activity on 
Gram-negative bacteria. Some peptides studied in this PhD work, led to a significant 
decrease of P. aeruginosa biofilm thickness and cell viability at concentration much 
lower than MIC values observed on planktonic growth [e.g. Apo B(887-911) and at a 
lower extent PA 3(26-47)]. Besides, our novel AMPs are able to modulate innate 
immune response, indeed, a general reduction of TNF-α pro-inflammatory cytokine 
was observed on PBMCs ( innate immune cells) treated with most of the peptides 
tested at very low concentration (5 µg/ml). Furthermore, almost all human peptides 
increased levels of MCP-1 secretion compared to untreated cells suggesting a role in 
the control of infection.  
Even if at the moment the panel of peptides and of assays performed is quite limited 
our preliminary data suggest that the in silico-derived list of potential AMPs is a rich 
source of peptides with pharmacologically relevant properties. 
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Abstract
Commercial uses of bioactive peptides require low cost, effective methods for their produc-
tion. We developed a new carrier protein for high yield production of recombinant peptides
in Escherichia coli very well suited for the production of toxic peptides like antimicrobial pep-
tides. GKY20, a short antimicrobial peptide derived from the C-terminus of human thrombin,
was fused to the C-terminus of Onconase, a small ribonuclease (104 amino acids), which
efficiently drove the peptide into inclusion bodies with very high expression levels (about
200–250 mg/L). After purification of the fusion protein by immobilized metal ion affinity chro-
matography, peptide was obtained by chemical cleavage in diluted acetic acid of an acid
labile Asp-Pro sequence with more than 95% efficiency. To improve peptide purification,
Onconase was mutated to eliminate all acid labile sequences thus reducing the release of
unwanted peptides during the acid cleavage. Mutations were chosen to preserve the differ-
ential solubility of Onconase as function of pH, which allows its selective precipitation at
neutral pH after the cleavage. The improved carrier allowed the production of 15–18 mg of
recombinant peptide per liter of culture with 96–98% purity without the need of further chro-
matographic steps after the acid cleavage. The antimicrobial activity of the recombinant
peptide, with an additional proline at the N-terminus, was tested on Gram-negative and
Gram-positive strains and was found to be identical to that measured for synthetic GKY20.
This finding suggests that N-terminal proline residue does not change the antimicrobial
properties of recombinant (P)GKY20. The improved carrier, which does not contain cyste-
ine and methionine residues, Asp-Pro and Asn-Gly sequences, is well suited for the produc-
tion of peptides using any of the most popular chemical cleavage methods.
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Introduction
Peptides of length between five and fifty residues have many applications in research, diagnostic,
medicine (e.g. antimicrobial [1, 2], anti-inflammatory [3], anti-cancer [4] and cell penetrating
peptides [5] etc.) and industry (e.g. metal surface-binding [6] and graphite-binding peptides [7]).
Solid phase chemical synthesis is well suited to obtain small amounts of peptides but it could be
rather expensive when peptides longer than 30 amino acids or high quantities of peptide are
required. On the other hand, recombinant production of peptides [8–11] entails several difficul-
ties. For example, expression of some peptides can be toxic for the host and several peptides are
very sensitive to proteases thus leading to low yields. These difficulties can be circumvented by
fusing the desired peptide to a carrier protein that can protect peptides from proteases, neutralize
possible toxic effects and provide a convenient route for their purification. However, also fusion
protein strategy has two main drawbacks. Firstly, the fusion protein has to be cleaved and pep-
tide needs to be separated from the carrier, secondly, the desired peptide usually represents just a
small percentage of the purified fusion protein. As for the cleavage of the peptide, it can be
released from the fusion protein by enzymatic or chemical cleavage at a site suitably introduced
at the carrier-peptide junction ([10] and references therein). The efficiency and specificity of the
cleavage is the main bottleneck of fused peptide production. Usually enzymatic proteolysis by
factor Xa [12, 13], enterokinase [14] and thrombin [15, 16], the most used enzymes, is less effi-
cient than chemical cleavage [17–19]. The lower efficiency of enzymatic methods is generally
attributed to unfavorable surrounding residues and/or to steric hindrance which make the cleav-
age sites not fully accessible. Furthermore, enzymes usually require non-denaturing reaction
conditions to work properly. Thus, enzymatic proteolysis cannot be used when the fusion pro-
tein is partly or completely insoluble. On the other hand, the most popular cleavage reagents,
like cyanogen bromide (CNBr), formic acid and hydroxylamine, which cleave Met-X, Asp-Pro
and Asn-Gly peptide bonds [10, 20, 21], respectively, often produce unwanted cleavages and
side-chain modifications due to the harsh reaction conditions needed for the cleavage [22–28].
For example, cleavage of Asp-Pro sequences, usually performed at 60°C in 50–70% formic acid,
often results in unspecific hydrolysis, formylation and oxidation reactions of side chains [28].
Here, we describe the rational development of a new carrier protein for high yield produc-
tion of recombinant peptides in Escherichia coli very well suited for toxic peptides like antimi-
crobial peptides [10]. The denatured form of Onconase (ONC), a RNase from Rana pipiens
[29], was chosen as starting point to design the carrier protein. ONC is a very well suited part-
ner for several reasons: (i) it can be expressed at very high levels in inclusion bodies (about
200–250 mg/L in terrific broth); (ii) usually no soluble ONC can be detected in growth cultures
thus minimizing the risk of toxic effects of the ONC-peptide fusion proteins; (iii) it is a very
small protein (104 aa) thus allowing high yields of the peptides after the cleavage; (iv) the solu-
bility of denatured Onconase is pH dependent—the denatured protein is soluble only at pH
<4 –thus allowing the purification of peptides soluble at pH 7 by selective precipitation of the
carrier. Moreover, ONC does not contain Asp-Pro and Asn-Gly sequences and the mutant
(M23L)-ONC [30] does not contain internal methionine residues, therefore it is compatible
with all common chemical cleavage strategies.
Starting from mutant (M23L)-ONC we have developed an improved carrier protein bearing
15 mutations and an improved cleavage procedure of Asp-Pro peptide bonds that does not
require formic acid.
We tested the efficiency of our strategy by producing GKY20, a short cationic antimicrobial
peptide derived from the C-terminus of human thrombin [31]. Like other similar antimicrobial
peptides, GKY20 is endowed with broad spectrum antimicrobial activity being active both on
Gram-positive and Gram-negative bacteria. Its bactericidal activity has been attributed to its
Design of a Carrier Protein for Recombinant Peptide Production
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capacity to induce membrane lysis. Moreover, it shows potent anti-inflammatory activity due
to its ability to bind LPS thus inhibiting macrophage responses to these components of the
outer membrane [32]. Noteworthy, GKY20 is active on different strains of E. coli with a mini-
mal inhibitory concentration (MIC) lower than 10 μM [33]. In spite of this high toxicity we
were able to prepare recombinant GKY20 in E. coli with final yield of about 15–20 mg per L of
culture and purity higher than 96–98%.
Results and Discussion
Expression vector design: ONC-(P)GKY20 fusion protein
Native ONC is a small protein (104 aa) stabilized by four disulfide bridges. When expressed in
E. coli, wild type ONC and its mutants are produced at high yield as inclusion bodies [29, 30].
We have previously shown that once extracted by denaturation using guanidine chloride and
dialyzed in acetic acid 0.1 M the denatured form is very soluble, whereas at pH 7 it is prone to
aggregation and efficient renaturation can only be achieved by a special procedure based on
reversible blocking of cysteine residues [29]. In order to use denatured ONC as carrier for the
production of recombinant peptide GKY20, we prepared a chimeric open reading frame
including codons 1–103 of (M23L)-ONC [34], five codons coding for a linker sequence
(GTGDP) containing the formic acid cleavable aspartyl-prolyl dipeptide, and a sequence cod-
ing for GKY20 (Fig 1A and S1 File, panel A). This sequence was obtained by changing six
codons in the human coding sequence to better match E. coli codon usage (S1 File, panel C). It
should be reminded that ONC does not contain Asp-Pro and Asn-Gly sequences (S1 File,
panel A). Moreover, mutant (M23L)-ONC does not contain any internal methionine residue.
Thus, mutant (M23L)-ONC represents an ideal scaffold for the chimeric construct because it is
not cleaved by the usual chemical cleavage strategies.
The linker sequence was chosen both to introduce a flexible region into the chimeric protein
between the ONCmoiety and GKY20 and to introduce two restriction enzyme sites, KpnI
(codons coding for amino acids GT) and BamHI (codons coding for amino acids GDP). More-
over, C-terminal cysteine of the ONC moiety (Cys104) was deleted to avoid the presence of an
oxidation prone residue near to the cleavage site. The synthetic construct and the correspond-
ing recombinant protein were named ONC-(P)GKY20 to underline that, by acid cleavage, the
recombinant protein releases peptide (P)GKY20 i.e. peptide GKY20 with an additional proline
at the N-terminus. The construct was cloned into pET22b(+) plasmid between NdeI and SacI
restriction sites (Fig 1A) and expressed into BL21(DE3) E. coli cells. Expression of recombinant
protein was obtained as described in Materials and Methods.
SDS-PAGE analysis of induced cultures (Fig 2) showed high expression levels of ONC-(P)
GKY20 (200–250 mg/L) as inclusion bodies. The recombinant protein was partially purified by
denaturation of the inclusion bodies and dialysis in 0.1 M acetic acid pH 2.9 that causes the
precipitation of most of the E. coli proteins. As shown in Fig 2 (lane 4), after dialysis the soluble
fraction contained less than 15–20% of E. coli proteins as determined by SDS-PAGE densitom-
etry scan. This sample was used to optimize the acidic cleavage of the DP sequence as described
in the next section.
Chemical cleavage optimization of aspartyl-prolyl bonds in ONC-(P)
GKY20 fusion protein
The cleavage of Asp-Pro sequences is usually performed at temperatures in the range 55–80°C
in 50–75% formic acid. However, these reaction conditions often produce unwanted side reac-
tions like formylation and unspecific hydrolysis [22–28].
Design of a Carrier Protein for Recombinant Peptide Production
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In order to find less harsh cleavage conditions, thermal incubations of ONC-(P)GKY20
fusion protein were carried out in different acid solutions: 50%, 60% or 70% formic acid (Fig
3A), 0.1 M acetic acid (pH 2.9), 0.1 M acetic acid adjusted at pH 2.0 with HCl (Fig 3B). Samples
were incubated at 50° or 60°C for 3, 6, 9, 15 or 24 h. With the exception of 0.1 M acetic acid pH
Fig 1. Schematic representation of expression vectors and recombinant proteins. Fusion proteins without (A) and with (B) His6-Tag. The main
restriction enzyme sites,NdeI, EcoRI, KpnI, BamHI and SacI were reported. MCS: multicloning site. Onconase: carrier protein (grey). Linker: DNA sequence
coding for GTGDP amino acid residues (red). GKY20: human Thrombin derived peptide (blue).
doi:10.1371/journal.pone.0146552.g001
Fig 2. Protein expression. SDS-PAGE analysis of ONC-(P)GKY20 and ONC-DCless-H6-(P)GKY20 fusion
proteins. Lane M1: marker (14.3 kDa). Lanes 1–4, ONC-(P)GKY20 protein: lane 1, cell lysate of induced
culture; lane 2, insoluble fraction after cell lysis; lane 3, soluble fraction after cell lysis; lane 4, purified ONC-
(P)GKY20 recombinant protein after dialysis against 0.1 M acetic acid. Lane M2: marker (8-12-20-30-45-60-
100-220 kDa proteins). Lanes 5–8, ONC-DCless-H6-(P)GKY20 fusion protein: lane 5, cell lysate of induced
culture; lane 6, insoluble fraction after cell lysis; lane 7, soluble fraction after cell lysis; lane 8, inclusion bodies
after triton/urea wash.
doi:10.1371/journal.pone.0146552.g002
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2.9 (Fig 3B), all the acidic solutions resulted in the efficient hydrolysis (>90%) of the recombi-
nant fusion protein by incubating samples at 60°C for times 15 h, but with a significant dif-
ference: in the case of the acetic acid solution at pH 2.0, a specific cleavage pattern with the
formation of six discrete polypeptide bands was visible on SDS-PAGE (Fig 3B), whereas in the
case of formic acid, in addition to the bands observed in the case of the acetic acid/HCl hydro-
lysis, a smear was clearly evident suggesting the occurrence of unspecific cleavages (Fig 3A).
This experiment indicated that it is possible to cleave the recombinant protein without
using high concentrations of organic acids, but unfortunately they also revealed two unex-
pected problems: i) mild acidic hydrolysis cleaved ONC-(P)GKY20 in several fragments (Fig
3B) in spite of the fact that it contains a single Asp-Pro sequence between ONC and GKY20; ii)
some E. coli proteins, present in small amount as contaminants in the inclusion bodies, also
Fig 3. Hydrolysis pattern of ONC-(P)GKY20 protein. Samples were cleaved at acid pH for 24 h at 60°C
and analyzed on 20% SDS-PAGE. Lane M: marker (14.3 kDa). Lanes 1, 5: purified fusion protein. (A) ONC-
(P)GKY20 protein hydrolyzed in 50% (lane 2), 60% (lane 3) e 70% (lane 4) formic acid (60°C, 24 h). (B) ONC-
(P)GKY20 protein hydrolyzed in 0.1 M acetic acid, pH 2.9, (lane 6) and in 0.1 M acetic acid adjusted at pH 2.0
with HCl (lane 7); the N—terminal sequences of the fragments obtained by hydrolysis of ONC-(P)GKY20
fusion protein (lane 6) were as follow: fragment 1, PGK [(P)GKY20 peptide)] and MQD (N-terminal peptide,
less represented); fragment 2, X(Cys)NVT (D67-C68 cleavage site); fragment 3, X(Cys)NVT (D67-C68
cleavage site) and MQD (N-terminal peptide, less represented); fragment 4, X(Cys)DNI (D18-C19 cleavage
site); fragments 5 and 6, MQD (N-terminal region) which represent the carrier protein and uncleaved fusion
protein respectively. (C) Amino acid sequence of ONC-(P)GKY20 fusion protein; the main cleavage sites are
underlined.
doi:10.1371/journal.pone.0146552.g003
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underwent cleavage releasing shorter fragments as evidenced by the disappearance of high
molecular weight bands.
N-terminal sequencing of the fragments separated by SDS-PAGE (Fig 3B), allowed to iden-
tify three main sites of cleavage in the fusion protein. In addition to the expected cleavage at
the Asp-Pro sequence in the linker sequence, which releases the desired peptide (P)GKY20,
two unexpected sites of hydrolysis were identified: Asp18-Cys19 and Asp67-Cys68. An incom-
plete hydrolysis at these sites accounts for the six bands observed in the SDS-PAGE (Fig 3B).
Band 1 contained (P)GKY20 and a peptide corresponding to the N-terminus of ONC (includ-
ing initial methionine). Intermediate bands were due to fragments starting at Cys19 and Cys68.
Bands 5 and 6 contained fragments starting at the N-terminal sequence of ONC. On the basis
of their migration they are likely the uncleaved fusion protein (band 6) and the ONC moiety
resulting from a single cleavage at the Asp-Pro sequence (band 5). To the best of our knowledge
this is the first report of efficient acid induced cleavage at Asp-Cys sequences.
On the basis of these observations we concluded that the acid cleavage with 0.1 M acetic
acid pH 2.0 of ONC-(P)GKY20 fusion protein could not be used to obtain pure (P)GKY20
peptide. Thus, we decided to try to improve the carrier sequence (i) to overcome the undesired
cleavages we have observed, and (ii) to avoid the formation of the short fragments derived
from the hydrolysis of contaminant E. coli proteins.
Improvement of the carrier sequence: first generation mutants
Improvement of the Onconase carrier was performed by a trial and error procedure. For sim-
plicity in Table 1 several different versions of the carrier are divided into "first generation” and
“second generation” fusion proteins.
The mutations introduced into the first generation proteins were chosen mainly to remove
the unexpected Asp-Cys cleavage sites and to obtain a high purity fusion protein in order to
reduce the release of unwanted peptides during the acid cleavage step from contaminant E. coli
proteins.
As for unexpected Asp-Cys cleavage sites, sequences Asp-Cys were mutated to Asp-Tyr and
Glu-Tyr. Mutations were chosen to preserve the propensity of denatured ONC to form inclu-
sion bodies and to aggregate at pH 7. Since protein solubility and propensity to form aggre-
gates, like inclusion bodies, are generally related to net charge, hydrophobicity and to the
presence of amphipatic secondary structures [35, 36], the amino acid substitutions were chosen
in order to preserve these properties. Therefore, aspartic acid residues were replaced with glu-
tamic acid residues in order to preserve the net charge. Cysteine residues were replaced with
tyrosine residues as in several hydrophobicity scales these two residues show very similar
hydrophobicity scores [37]. Moreover, the replacement of Asp-Cys with Glu-Tyr allows to
keep unchanged secondary structure propensity since the replacement of aspartate with gluta-
mate decreases the preference for loop structures, whereas the replacement of cysteine with
tyrosine increases the preference for loop structures. Furthermore, the mutant bearing the two
Glu-Tyr sequences was also prepared with a six histidine-tag sequence (H6) inserted between
the ONC moiety and the flexible linker GTGDP (Fig 1B).
All the recombinant fusion proteins showed high expression levels as inclusion bodies, thus
indicating that the chosen mutations did not interfere with the formation of inclusion bodies
(Fig 4).
When Asp-Cys sequences were changed to Asp-Tyr [ONC(YY)-(P)GKY20 fusion protein]
or to Glu-Tyr [ONC(EYEY)-(P)GKY20 fusion protein] a drastic reduction of unwanted acid
cleavage in 0.1 M acetic acid pH 2.0 at 60°C for 24 h was observed (Fig 5A and 5B, respec-
tively). The SDS-PAGE analysis of the cleavage products of ONC(YY)-(P)GKY20 and ONC
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(EYEY)-(P)GKY20 was similar but not identical. In particular only ONC(YY)-(P)GKY20
reproducibly showed a smear corresponding to bands 2 and 3 in the analysis of ONC-(P)
GKY20 (Fig 5A), thus suggesting that only mutation Asp-Cys to Glu-Tyr abolished the cleav-
age at the bond Asp67-Cys68. On the contrary both mutants showed two close bands (Fig 5A
and 5B, respectively) whose migration is similar to that of band 4, attributed to the cleavage at
the bond Asp18-Cys19. As mentioned in the previous section the disappearance of high molec-
ular weight bands suggested the release of unwanted peptides produced during the acid cleav-
age step from contaminant E. coli proteins (Fig 5B). Therefore, we decided to increase the
purity of the protein sample subjected to acid hydrolysis by the addition of a H6 tag sequence
to the chimeric proteins. ONC(EYEY)-H6-(P)GKY20 mutant was produced and purified as
Table 1. Expression vectors, fusion proteins and peptides.
Expression vectors Fusion proteins Linker and Cleavage site Peptides Peptide (N-terminal end)
First generation fusion proteins
pET22b(+)/ONC-(P)GKY20 ONC-(P)GKY20a GTGDP GKY.. (P)GKY20 P-GKY. . .
pET22b(+)/ONC(YY)-(P)GKY20 ONC(YY)-(P)GKY20b GTGDP GKY.. (P)GKY20 P-GKY. . .
pET22b(+)/ONC(EYEY)-(P)GKY20 ONC(EYEY)-(P)GKY20c GTGDP GKY.. (P)GKY20 P-GKY. . .
pET22b(+)/ONC(EYEY)-H6-(P)GKY20 ONC(EYEY)-H6-(P)GKY20d GTGDP GKY.. (P)GKY20 P-GKY. . .
Second generation fusion proteins
pET22b(+)/ONC-DCless-H6-(P)GKY20 ONC-DCless-H6-(P)GKY20e GTGDP GKY.. (P)GKY20 P-GKY. . .
pET22b(+)/ONC-DCless-H6-(PM)GKY20 ONC-DCless-H6-(PM)GKY20e GTGDPM GKY.. (PM)GKY20 PM-GKY. . .
- - - GKY20 GKY. . .
a ONC: Onconase mutant-M23L,C104 delete;
b ONC(YY): Onconase mutant-M23L,C19Y,C68Y,C104 delete;
c ONC(EYEY): Onconase mutant-M23L,D18E,C19Y,D67E,C68Y,C104 delete;
d ONC(EYEY)-H6: Onconase mutant-M23L,D18E,C19Y,D67E,C68Y,C104 delete; H6: Hexa-histidine tag at the C-terminal side of the onconase carrier.
e ONC-DCless-H6: Onconase mutant-M23L,D2E,D16E,D18E,C19Y,D20E,C30Y,D32E,C48L,D67E,C68Y,C75Y,C87I,C90I,C104 delete; H6: Hexa-
histidine tag at the C-terminal side of the onconase carrier.
doi:10.1371/journal.pone.0146552.t001
Fig 4. Protein expression of first generation mutants. (A) SDS-PAGE analysis of insoluble (lanes 1, 3)
and soluble (lanes 2, 4) fractions after cell lysis of ONC(YY)-(P)GKY20 and ONC(EYEY)-(P)GKY20 fusion
proteins, respectively. (B) SDS-PAGE analysis of soluble (lane 5) and insoluble (lane 6) fractions after cell
lysis of ONC(EYEY)-H6-(P)GKY20 fusion protein. Lane M: marker (14.3 kDa).
doi:10.1371/journal.pone.0146552.g004
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described in Materials and Methods. As it is shown in Fig 5, the addition of the H6 tag signifi-
cantly improved the purity of the chimeric protein from about 80% (Fig 5B) to more than 96–
98% as determined by SDS-PAGE densitometry scan (Fig 5C), with a recovery of about 95% of
the total fusion protein. Purified ONC(EYEY)-H6-(P)GKY20 was subjected to acid cleavage in
0.1 M acetic acid pH 2.0 at 60°C for 24 h as described above. SDS-PAGE analysis of ONC
(EYEY)-H6-(P)GKY20 acid cleavage mixtures (Fig 5C) still evidenced the presence of the two
faint bands observed in the case of ONC(EYEY)-(P)GKY20 thus demonstrating that these
bands derive from cleavage of the fusion proteins and not from the contaminants. Taken
together, our data suggested that, in addition to the bonds Asp18-Cys19 and Asp67-Cys68, fur-
ther acid labile bonds are present in Onconase. Studies on protein and peptide aging have dem-
onstrated that all Asp-X bonds can undergo spontaneous hydrolysis, even if at a lesser extent
than the Asp-Pro bond [38–40]. For example, Joshi and co-workers [39, 40] demonstrated that
at acidic pH glucagon undergoes degradation due to hydrolysis at the Asp9-Tyr10 and Asp15--
Ser16 bonds and at a lesser extent at the Asp21-Phe22 bond. These findings are in agreement
with our conclusion that Asp67-Tyr68 in ONC(YY)-(P)GKY20 fusion protein contributes to
the release of ONC derived fragments and suggest that one or more of the additional Asp-X
sequences present in the ONC moiety (Asp2-Trp3, Asp16-Val17, Asp20-Asn21 and
Asp30-Lys31) could be sensitive to acid hydrolysis. In particular one or both the two close
bands observed in the hydrolysis products of ONC(YY)-(P)GKY20 and ONC(EYEY)-(P)
GKY20 fusion protein could be tentatively attributed to cleavage at the Asp16-Val17 and/or
Asp20-Asn21 and/or Asp-30-Lys31 bonds.
Improvement of the carrier sequence: second generation mutants
Mutations introduced into the second generation protein ONC-DCless-H6-(P)GKY20 were
chosen to remove all the potential unwanted cleavage sites and to reduce the possibility of
unwanted formation of intra-chain disulfides without changing the expression level of the
fusion protein, its propensity to form inclusion bodies in E. coli and the propensity of dena-
tured Onconase to form large aggregates at pH higher than 5 as this feature is very useful to
Fig 5. Comparison of hydrolysis patterns of first and second generation mutants.Chemical cleavage was carried out in 0.1 M acetic acid adjusted at
pH 2.0 with HCl (60°C, 24 h). Samples were analyzed on 20% SDS-PAGE. Lane M1: markers (13.8 kDa, 11.8 kDa). Lane M2: RK-16 peptide (1961.25 Da).
Lane M3: marker (14.3 kDa). (A) ONC(YY)-(P)GKY20 purified fusion protein (lane 1) and hydrolyzed protein (lanes 2–4, three independent experiments).
ONC-(P)GKY20 purified protein (lane 5) and cleaved protein (lane 6). (B, C, D) ONC(EYEY)-(P)GKY20, ONC(EYEY)-H6-(P)GKY20 and ONC-DCless-H6-
(P)GKY20 purified fusion proteins (lanes 7, 9, 11, respectively), and hydrolyzed proteins (lane 8, 10, 12, respectively). Onc-P: Onconase/Peptide fusion
protein; Onc: Onconase carrier; P: (P)GKY20 peptide. Fragments obtained by hydrolysis of ONC-(P)GKY20 fusion protein (B, lane 6) are numbered as in Fig
3.
doi:10.1371/journal.pone.0146552.g005
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remove the carrier after the acid cleavage by means of a simple centrifugation step (as described
below). To this aim, as discussed for the first generation mutants, the four remaining aspartic
acid residues in the ONC moiety were replaced with glutamic acid residues to preserve the
charge and all the cysteine residues were mutated to other residues of similar or higher hydro-
phobicity chosen on the basis of the secondary structure of native ONC. Accordingly, the single
cysteine residue (Cys48) present within alpha helix 3 (S2 File) was replaced with a leucine resi-
due (a “helix-preferring” residue). The two cysteine residues located in beta strands (Cys87 and
Cys90) were replaced with isoleucine (a “beta-preferring” residue). Finally, two cysteine resi-
dues located in loops (Cys30 and Cys75) were replaced with tyrosine residues. It should be
noted that the mutation of cysteine to leucine or isoleucine increases significantly the hydro-
phobicity and, likely, the propensity of the protein to aggregate.
ONC-DCless-H6-(P)GKY20 (Table 1), was produced in the form of inclusion bodies with a
yield similar or higher than that observed for ONC-(P)GKY20 (Fig 2), thus demonstrating that
the amino acid substitutions into the carrier sequence did not influence protein expression lev-
els. After purification on Ni-sepharose, ONC-DCless-H6-(P)GKY20 showed about 98% purity
as determined by SDS-PAGE densitometry scan (Fig 5D), with a recovery of about 95%.
After cleavage in 0.1 M acetic acid adjusted at pH 2.0, at 60°C for 24 h, SDS-PAGE analysis
allowed to estimate 95% efficiency in the release of (P)GKY20. It is worth noting that no
unwanted cleavage was observed, thus confirming that aspartic acid residues were responsible for
the low efficiency cleavages observed in the case of ONC(EYEY)-H6-(P)GKY20 protein (Fig 5D).
Adjusting the pH to 7.2–7.4 with NH3 and incubating the mixture at 28°C for 16 h the
uncleaved ONC-DCless-H6-(P)GKY20 and ONC-DCless-H6 proteins formed macroscopic
insoluble aggregates which were completely removed by centrifugation (Fig 6). Peptide (P)
GKY20 was recovered in the soluble fraction, lyophilized and used for the characterization
described below without any further purification step. Mass spectrometry analysis (Fig 7A),
confirmed the peptide identity and showed that no modified form (e.g. oxidized or formylated
peptides) was present in the sample.
Final purity of (P)GKY20 peptide, as determined by reverse phase chromatography (Fig
7B), typically ranged from 95% to 99%.
The optimized procedure allowed the purification of about 10–11 mg of peptide starting
from 100 mg of purified fusion protein with 70–75% recovery efficiency (actual milligrams of
peptide/expected milligrams of peptide) with respect to the theoretical amount of peptide in
the fusion protein.
Cleavage by cyanogen bromide of ONC-DCless-H6-(PM)GKY20 fusion
protein
Starting from ONC-DCless-H6-(P)GKY20 we prepared mutant ONC-DCless-H6-(PM)
GKY20. In this fusion protein the additional mutation, a single amino acid insertion, is located
in the peptide moiety rather than in the ONCmoiety which is identical to that of ONC-DC-
less-H6-(P)GKY20. By acid hydrolysis it releases peptide (PM)GKY20 carrying two additional
residues at the N-terminus. However, as ONC-DCless-H6 does not contain methionine resi-
dues, ONC-DCless-H6-(PM)GKY20 fusion protein can also be cleaved using CNBr to release
the peptide GKY20 which does not have any additional residue at the N-terminus.
By acid cleavage ONC-DCless-H6-(PM)GKY20 provided results identical to those obtained
in the case of ONC-DCless-H6-(P)GKY20 (Fig 8), thus showing that the additional methionine
residue following the Asp-Pro sequence has no influence on the acid cleavage efficiency.
ONC-DCless-H6-(PM)GKY20 fusion protein was also cleaved by using CNBr in 0.2 M HCl
as described in details in the Material and Methods section. As shown in Fig 9 the efficiency of
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cleavage (about 80%, as determined by SDS-PAGE densitometry scan) was only slightly lower
than that obtained with acid hydrolysis, thus demonstrating that ONC-DCless-H6-(PM)
GKY20 fusion protein can be effectively cleaved by both chemical methods.
Antimicrobial activity
In order to verify if recombinant peptide (P)GKY20 possesses antimicrobial activity compara-
ble to that of a synthetic GKY20, both peptides were tested by plate viable-count assay on a
Gram-positive strain, Staphylococcus aureus ATCC 6538P, and a Gram-negative strain, Pseu-
domonas aeruginosa KK27 [a clinical strain isolated from a cystic fibrosis patient kindly pro-
vided by Dr. Alessandra Bragonzi (San Raffaele Hospital, Milan)]. As shown in Fig 10, the
antimicrobial activity of (P)GKY20 was identical to that measured for synthetic GKY20.
Moreover, to further investigate if N-terminal proline of (P)GKY20 affected the potency of
the peptide, we determined, by broth microdilution method, the MIC values (the lowest con-
centration of antimicrobial agent at which no growth is observed) of the two peptides. As
shown in Table 2 and Fig 11, peptides exhibited the same MIC values towards several Gram-
positive and Gram-negative strains. These data are very close to those determined against E.
coli and S. aureus strains for synthetic C-terminal human thrombin peptides [33]. Taken
together, these findings suggest that N-terminal proline residue does not change the antimicro-
bial properties of recombinant (P)GKY20.
Conclusions
Through a rational design strategy we have progressively improved the suitability of ONC as a
carrier for the production of recombinant peptides. The final version of the protein, ONC-DC-
less-H6, may likely be a very efficient carrier particularly suited for the production of peptides
expected to be very toxic for the host E. coli like antimicrobial peptides. It is expressed at high
levels (>200 mg/L) efficiently forming inclusion bodies, and thus sequestering the hosted
Fig 6. Purification of recombinant (P)GKY20 peptide.DS-PAGE (20%) analysis. Lane M: marker (14.3
kDa). Lane 1: ONC-DCless-H6-(P)GKY20 fusion protein purified by IMAC. Lane 2: cleaved fusion protein
(0.1 M acetic acid adjusted at pH 2.0 with HCl, 60°C, 24 h). Lane 3: soluble fraction after neutralization of the
cleavage reaction [(P)GKY20 peptide]. Lane 4: insoluble fraction after neutralization of the cleavage reaction
(uncleaved fusion protein and Onconase cleaved carrier). Onc-P: Onconase/Peptide fusion protein; Onc:
Onconase carrier; P: (P)GKY20 peptide.
doi:10.1371/journal.pone.0146552.g006
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peptide in an insoluble form. Once solubilized by chaotropic agents the chimeric protein can
be easily purified by Ni-chelate chromatography without the need of removing the denaturing
agent. At pH lower than 4 denatured ONC is very soluble, therefore chemical cleavage proce-
dures that require an acidic environment (e.g. cleavage of aspartyl-prolyl bonds and CNBr
cleavage) can be performed also in diluted acids such as 0.1 M acetic acid or HCl without the
need to employ high concentrations of formic acid that is often chosen for its denturing/solubi-
lizing properties [28, 41] but, as already mentioned, causes several unwanted reactions. After
the cleavage at acidic pH, the ONC moiety, ONC-DCless-H6, can be easily removed due to its
Fig 7. Characterization of purified recombinant (P)GKY20 peptide. (A) Mass spectrum of purified (P)GKY20 peptide. The measured molecular weight
(2609.47 Da) is consistent with the theoretical value (2609.1 Da). (B) Reverse-phase HPLC chromatogram recorded at 280 nm wavelength. Purified peptide
was applied to a C18 column (Jupiter 5u C18 300Å, 250 x 4.6 mm) and eluted with a linear gradient from 5% to 95% acetonitrile containing 0.05%
trifluoroacetic acid, over 60 min at flow rate of 1 mL/min.
doi:10.1371/journal.pone.0146552.g007
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Fig 8. Asp-Pro cleavage efficiency comparison of ONC-DCless-H6-(P)GKY20 and ONC-DCless-H6-
(PM)GKY20 fusion proteins. Samples were cleaved in 0.1 M acetic acid adjusted at pH 2.0 with HCl (60°C,
24 h) and analyzed on 20% SDS-PAGE. Lane M: marker (14.3 kDa). Lane 1: ONC-DCless-H6-(PM)GKY20
purified fusion protein. Lanes 2, 3: ONC-DCless-H6-(PM)GKY20 (lane 2) and ONC-DCless-H6-(P)GKY20
(lane 3) hydrolyzed proteins. Onc-P: Onconase/Peptide fusion protein; Onc: Onconase carrier; P: (P)GKY20
peptide.
doi:10.1371/journal.pone.0146552.g008
Fig 9. Cyanogen bromide cleavage of ONC-DCless-H6-(PM)GKY20 fusion protein. Samples were
analyzed on 20% SDS-PAGE. Lane M: marker (14.3 kDa). Lane 1, purified fusion protein. Lanes 2, 3:
cleaved recombinant protein in 0.2 M HCl with 100- (lane 2) and 400-fold (lane 3) molar excess of CNBr over
methionine residues. Sample were incubated in the dark at room temperature for 24 h. Onc-P: Onconase/
Peptide fusion protein; Onc: Onconase carrier; P: (P)GKY20 peptide.
doi:10.1371/journal.pone.0146552.g009
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complete insolubility at neutral pH. This feature may allow a simple and effective purification
of any peptide that is soluble at pH 7.0. Alternatively, the carrier could be removed under dena-
turing conditions by Ni-chelate chromatography as after acidic cleavage it retains the H6 tag.
Table 3 shows a comparison between our method and those reported in some recent papers
describing the production of recombinant antimicrobial peptides.
As for the cleavage of the hosted peptide, ONC-DCless-H6 is very versatile. As it does not
contain methionine residues nor Asp-Pro sequences or any other acid sensitive sequence,
Fig 10. Antibacterial activity of recombinant (P)GKY20 and synthetic GKY20 peptides. Assays were
carried out by viable-count method. (A) Staphylococcus aureus ATCC 6538P; (B) Pseudomonas aeruginosa
KK27. Dose-effect curves: 0.1–0.5-1-2-3 μM final concentrations were tested. Error bars are standard
deviations. Black circles: synthetic GKY20. White circles: (P)GKY20.
doi:10.1371/journal.pone.0146552.g010
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hosted peptides may be released either by CNBr or by acidic cleavage. Furthermore, as the
ONC scaffold does not contain any cysteine residues, peptides may also be released by using
2-nitro-5-thiocyanatobenzoic acid, a reagent that very specifically modify thiols causing the
cleavage of X-Cys bonds [20, 28], by replacing the DP or DPM sequences at the end of the flex-
ible linker with a cysteine.
Our strategy, due to its simplicity and limited costs, is also suited for the scale up and could
thus be useful for medium/large scale production of peptides needed, for example, in the clini-
cal trial phases.
Materials and Methods
Materials
Expression host strain E. coli BL21(DE3) and plasmid pET22b(+) were purchased from Nova-
gen (San Diego, CA, USA). E. coli strain TOP10F’ was obtained from Invitrogen (San Diego,
CA, USA). QIAprep spin miniprep kit was from Qiagen (Germantown, MD, USA). Wizard SV
Gel and PCR Clean-Up DNA Purification System for elution of DNA fragments from agarose
gel was purchased from Promega (Madison, WI, USA). Enzymes and other reagents for DNA
manipulation were from New England Biolabs (Ipswich, MA, USA). Ni Sepharose™ 6 Fast
Flow was from GE Healthcare (Uppsala, Sweden). The GKY20 peptide was chemically synthe-
sized by INBIOS s.r.l. (University of Naples, Italy). Difco Nutrient Broth was from Becton-
Dickenson (Franklin Lakes, NJ). All other chemicals were from Sigma-Aldrich (Milano, Italy).
General procedures
Bacterial cultures, plasmid purifications and DNA manipulation were carried out according to
Sambrook [42]. DNA sequences and oligonucleotide synthesis were performed by Eurofins
MWGOperon service (Ebersberg, Germany). Sodium Dodecyl Sulphate PolyAcrylamide Gel
Electrophoresis (SDS-PAGE) was carried out according to Laemmli [43]. Gallus gallus lyso-
zyme (14.3 kDa), human pancreatic RNase A (13.8 kDa), recombinant Onconase from Rana
pipiens (11.8 kDa) and RK-16 peptide from Salmo salar Ss-RNasi 1 [44] (16 aa: RYPH-
CRYRGSPPSTRK; theoretical molecular weight, 1961.25 Da) were used as molecular markers.
When appropriate, the relative amount of bands was determined by densitometry performed
Table 2. Antibacterial activity of Thrombin derived peptides.
MIC (μM)a
(P)GKY20 GKY20
Bacterial strain Replicatesb Replicatesb
E. coli DH5α 12.5 12.5 12.5 12.5 12.5 12.5
E. coli ATCC 25922 12.5 12.5 25 12.5 12.5 25
E. coli ATCC 35218 12.5 12.5 12.5 12.5 12.5 12.5
P. aeruginosa PAO1 25 12.5 25 25 12.5 25
P. aeruginosa PA14 50 50 25 50 50 25
S. aureus ATCC 6538P 6.25 3.12 6.25 6.25 3.12 6.25
K. pneumoniae ATCC 700603 12.5 12.5 12.5 12.5 12.5 12.5
B. megaterium SF185 12.5 12.5 12.5 12.5 12.5 12.5
aAssays were carried out by broth dilution method in Nutrient Broth 0,5 X.
bReplicates were from three independent experiments.
doi:10.1371/journal.pone.0146552.t002
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using the Gel Doc™ XR system (Bio-Rad Laboratories, Inc.) equipped with the Quantity One1
Software. Protein concentration was determined by the Bradford Protein Assay (Sigma-
Aldrich, St. Louis, MO, USA) and standard curves were generated using bovine serum albumin
(BSA). Concentrations of purified fusion proteins and peptides were determined by spectro-
photometric analysis using the extinction coefficients calculated using the ProtParam tool
(accessible to the address http://web.expasy.org/protparam/) [45]. Amino-terminal sequencing
was carried out on polypeptides separated by denaturing gel electrophoresis and then electro-
blotted onto polyvinylidene difluoride (PVDF) membranes [46].
Fig 11. Inhibition growth assay of E. coliDH5α (A) and S. aureusATCC 6538P (B). Assays were carried
out by broth dilution method in Nutrient Broth 0.5x. Bacteria from overnight culture were inoculated (~5x105
CFU/mL) in the presence of different concentration of tested peptides (0.2–100 μM). After incubation at 37°C
for 16 h, the minimum inhibitory concentration (MIC) was determined as the lowest concentration showing no
visible growth. All measurements were carried out three times in independent experiments.
doi:10.1371/journal.pone.0146552.g011
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Construction of the expression vectors
DNA sequences coding for fusion proteins reported in Table 1, were obtained by chemical syn-
thesis (MWG-Biotech AG; Ebersberg, Germany) or by PCR mutagenesis.
Synthetic genes coding for recombinant proteins ONC-(P)GKY20, ONC-DCless-H6-(P)
GKY20 and ONC-DCless-H6-(PM)GKY20 (Table 1) were obtained by MWG-Biotech AG
(Ebersberg, Germany). All codons were optimized for expression in E. coli and restriction sites
Table 3. Recently published papers reporting the production of recombinant antimicrobial peptides in Escherichia coli (E.c.) or Bacillus subtilis (B.
s.).
Reference Host Carriera number
of
peptides
Carrier features Puriﬁcation of
fusion
proteinsi
Cleavage
method
(efﬁciency)
Peptide
Puriﬁcationi
Peptide
yield
Peptide
purity
This paper E.c. ONC-DCless-
H6
2b Inclusion Bodies
forming/pH
dependent
solubility
Inclusion
Bodies
isolation & I.M.
A.C.
Diluted acid at
60°C for 18 h
(>95%) or CNBr
(~80%)j
Selective
precipitation
~ 15 to 18
mg/L (~ 13
to 16 mg/g
of dry cells)
>95%
[51] E.c. DAMP4var 2c Highly soluble
artiﬁcial
thermostable
protein
Two selective
precipitation
steps
Diluted acid at
60°C for 48 h
(high)
Selective
precipitation
Not reported Not
reportedm
[52] E.c. His tagged
ketosteroid
isomerase
2d Inclusion Bodies
forming
IB isolation & I.
M.A.C.
thrombin (80%-
95%)k
I.M.A.C. 30 mg/g of
dry cells
>95%
[53] E.c. His tagged
SUMOa
1e Soluble I.M.A.C. SUMO protease
(complete)
I.M.A.C. Not reported >95%
[54] B.s. His tagged
SUMOa
1f Soluble I.M.A.C. SUMO protease
cleavage
I.M.A.C. 5.5 mg/L
(0.16 mg/g
of wet cellsl)
>94%
[55] E.c. Chitin binding
domain/Intein
fusiona
1g Soluble/chitin
binding/auto-
proteolytic
Adsorption to
chitin beads (at
4°C)
auto-proteolysis
at 25°C for 16 h
(~50%)
RP-HPLC 1.7 mg/L Not
reported
[56] B.s. His tagged
thioredoxina
1h Soluble/Secreted selective
precipitation/I.
M.A.C
enterokinase
(complete)
I.M.A.C./
Cation
exchange
2 mg/L ~ 92%
aHis tagged ketosteroid isomerase, SUMO, CBD/Intein and thioredoxin-based methods are commercially available; here we report the most recent
applications based on these carriers.
bSequences of peptides (P)GKY20 and (PM)GKY20 are in S1 File.
cPS-Pexiganan-HH (PS-Pex-HH; PS-GIGKFLKKAKKFGKAFVKILKK-HH) and omiganan (GILRWPWWPWRRK-HHHHHH). Omiganan was expressed as
fusion protein but not further analysed.
dp53pAnt (GSRAHSSHLKSKKGQSTSRHKKWKMRRNQFWVKVQRG) and PNC27 (PPLSQETFSDLWKLLKKWKMRRNQFWVKVQRG).
eScorpine (GWINEEKIQKKIDERMGNTVLGGMAKAIVHKMAKNEFQCMANMDMLGNCEKHCQTSGEKGYCHGTKCKCGTPLSY).
fPlectasin (GFGCNGPWDEDDMQCHNHCKSIKGYKGGYCAKGGFVCKCY).
gP11-5 (GKLFKKILKIL)
hPR39, (RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP).
iDialysis and lyophilization steps are not indicated.
jMeasured only for ONC-DCless-H6-(PM)GKY20.
kOnly peptide p53pAnt could be cleaved by thrombin. 80% cleavage efﬁciency was obtained by incubating for 48h the fusion protein with thrombin,
whereas, 95% efﬁciency was reached by addition of fresh enzyme and further incubation.
lCalculated from data in ﬁgure 3 of reference 4.
mAuthors state that after the selective precipitation “. . .most of the DAMP4var was removed by centrifugation (Fig 7A, lane 2), and relatively pure PS-Pex-
HH was obtained for MIC testing (Fig 7A, lane 3 and Fig 7B)”.
doi:10.1371/journal.pone.0146552.t003
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NdeI and SacI were introduced at 5’- and 3’-end of the synthetic genes, respectively, for their
cloning into pET22b(+) vector (Fig 1; S1 File).
All other DNA sequences coding for mutants reported in Table 1 were obtained by Overlap
Extension PCRMutagenesis or by PCRMutagenesis [47] using the appropriate primers and
pET22b(+)/ONC-(P)GKY20 or pET22b(+)/ONC(EYEY)-(P)GKY20 plasmids as templates. PCR
reactions were carried out using the Phusion High Fidelity DNA Polymerase (Thermo Fisher,
New England Biolabs). PCR reactions were started by preheating samples at 94°C for 2 min.
Amplifications were performed as follows: 20 cycles at 94°C for 30 s, 56°C for 30 s and 72°C for
30 s, with a final elongation stage at 72°C for 10 min. Amplified products were digested with
the appropriate restriction enzymes for their cloning into the pET22b(+) vector. E. coli strain
TOP10F’ was used for all cloning procedures.
Expression of recombinant proteins
E. coli strain BL21(DE3) was used to express recombinant proteins. Cells, transformed with
pET recombinant plasmids, were grown in 10 mL of Terrific Broth medium (TB) containing
100 μg/ml ampicillin, at 37°C up to OD600nm of 2. These cultures were used to inoculate 1 L of
TB/ampicillin medium. Glucose at final concentration of 4 g/L was added to cultures to limit
protein expression before induction with IPTG. TB medium was found to be able to induce
protein expression over the early growth phase reducing the final optical density of cultures
and therefore the recombinant protein yield [48]. Cultures were incubated at 37°C up to
OD600nm of 3.5–4. Expression of recombinant proteins was induced by addition of IPTG (iso-
propyl-β-D-thiogalactopyranoside) at a final concentration of 0.4 mM. Cells were harvested
after overnight induction by centrifugation at 8000x g for 15 min at 4°C and washed with 50
mM Tris-HCl buffer, pH 7.4. The bacterial pellet was suspended in 50 mM Tris-HCl buffer,
pH 7.4, containing 10 mM ethylenediaminetetraacetic acid (EDTA), and sonicated in a cell dis-
ruptor (10 x 1 min cycle, on ice). The suspension was then centrifuged at 18,000 x g for 60 min
at 4°C. Soluble and insoluble fractions were analyzed by SDS-PAGE. The insoluble fractions
containing the recombinant protein as inclusion bodies, were washed three times in 0.1 M
Tris-HCl buffer, pH 7.4, containing 10 mM EDTA, 2% Triton X-100 and 2 M urea, followed
by repeated washes in 0.1 M Tris-HCl buffer, pH 7.4, to eliminate traces of Triton, urea and
EDTA. This procedure eliminated several contaminant proteins and cellular debris entrapped
in inclusion body pellets.
Purification of fusion proteins
To purify fusion proteins lacking His6-Tag, a procedure was developed to obtain partially puri-
fied protein without any chromatographic step. To this purpose, 100 mg of fusion proteins
were dissolved in 10 mL of denaturing buffer (6 M guanidine/HCl in 50 mM Tris-HCl, pH 7.4)
containing 10 mM β-mercaptoethanol. Mixtures were incubated at 37°C for 3 h under nitrogen
atmosphere on a rotary shaker, and then centrifuged at 18,000 x g for 60 min at 4°C. Soluble
fractions were collected by centrifugation and acidified to pH 3.0 by adding glacial acetic acid
before extensive dialysis against 0.1 M acetic acid at 4°C. Soluble fusion proteins were separated
from insoluble E. coli proteins by centrifugation and stored at -80°C under nitrogen
atmosphere.
His6-tagged recombinant proteins were purified by immobilized metal ion affinity chroma-
tography (IMAC), using the Ni Sepharose™ 6 Fast Flow resin. 100 mg of fusion proteins were
dissolved in 10 mL of denaturing buffer containing 10 mM β-mercaptoethanol and incubated
on a rotary shaker at 37°C for 3 h under nitrogen atmosphere. Soluble fractions were collected
by centrifugation and incubated with 5 mL of Ni Sepharose™ 6 Fast Flow resin equilibrated in
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denaturing buffer. The resin was shaken at 4°C for 16 h and then collected by centrifugation.
The supernatant, containing the unbound proteins, was discarded. The resin was washed three
times with 25 ml of denaturing buffer at 4°C for 30 min and then packed in a glass column.
The fusion proteins were eluted with 20 ml of 0.1 M sodium acetate buffer, pH 5.0, containing
6 M guanidine/HCl (elution buffer). The eluate was extensively dialyzed against 0.1 M acetic
acid at 4°C. Samples were stored at -80°C under nitrogen atmosphere. Purified fusion protein
concentrations were determined by spectrophotometric analysis using the extinction coeffi-
cients calculated using the ProtParam tool [ε280 = 24,410 M
_1 cm_1; ε280 (0.1%) = 1.53].
Cleavage optimization of Asp-Pro peptide bond
Fusion proteins were cleaved by thermal incubation in acid solutions under nitrogen atmo-
sphere. To optimize chemical cleavage, formic acid and acetic acid, were tested. Purified fusion
proteins in 0.1 M acetic acid were lyophilized and suspended in i) 50%, 60% and 70% formic
acid or ii) 0.1 M acetic acid at pH 2.9 or at pH 2.0 (by addition of diluted HCl). The mixtures
were incubated for 3-6-9-15-24 h, at 37°C, 50°C and 60°C. Cleavage efficiency was analyzed by
SDS-PAGE using 20% gel. Formaldehyde was used to covalently link proteins and polypeptides
in polyacrylamide gels [49]. To this purpose, 4% formaldehyde was added to the Coomassie
Blue staining solution (0.2% Coomassie Brilliant Blue R-250, 25% isopropyl alcohol and 10%
glacial acetic acid). Percentage of cleaved protein was determined by densitometric analysis of
SDS-PAGE gels as described in “General procedures”.
Identification of polypeptides obtained by chemical cleavage was carried out by N-terminal
sequencing. Proteins and polypeptides were separated by denaturing gel electrophoresis, elec-
troblotted onto polyvinylidene difluoride (PVDF) membranes, stained by Ponceau S dye and
sequenced by the Edman method [46].
Chemical cleavage and purification of recombinant (P)GKY20 peptide
Cleavage of the peptide from fusion proteins was performed in 0.1 M acetic acid at pH 2.0,
incubating samples at 60°C for 24 h in a water bath under nitrogen atmosphere. The mixtures
were then neutralized to pH 7–7.2 by adding NH3, purged with N2 and incubated at 28°C for
16 h in a water bath. The soluble peptide was isolated from the insoluble carrier through
repeated cycles of centrifugation at 18,000 x g for 60 min at 4°C. Purified peptide was lyophi-
lized and stored at -80°C. Peptide concentrations were determined by spectrophotometric anal-
ysis using the extinction coefficients calculated using the ProtParam tool [ε280 = 8,480 M
-1 cm-
1; recombinant (P)GKY20 peptide, ε280 (0.1%) = 3.250; GKY20 peptide, ε280 (0.1%) = 3.376].
The purity of (P)GKY20 peptide was verified by SDS-PAGE and reverse-phase HPLC using
a Waters (Milford, MA, USA) HPLC system (1525 binary pump and 2996 photodiode array
detector). The column was a C18 (250 x 4,6 mm, 5μm particle size) Jupiter 5u C18 300 Å (Phe-
nomenex). The solvents were 0.05% trifluoracetic acid (TFA) in water (solvent A) and 0.05%
TFA in acetonitrile (solvent B). The column was equilibrated with 5% acetonitrile and the pep-
tide was eluted by a linear gradient ranging from 5% to 95% solvent B over 60 min, at a flow
rate of 1 ml/min. The elution was monitored at 280 nm. Purity was determined by measuring
the relative area of peaks using the Empower software (Waters, Milford, MA, USA).
The identity of the peptide was determined by mass spectrometry. Positive Reflectron
MALDI spectra were recorded on a Voyager DE STR instrument (AB Sciex, Framingham,
MA). The MALDI matrix was prepared by dissolving α-cyano-hydroxycinnamic powder in
70% acetonitrile and 30% citric acid 50 mM. Typically 1 μL of matrix was applied to the metal-
lic sample plate and 1 μL of analyte was added. The mixture thus obtained was then dried at
room temperature. Acceleration and reflector voltages were set up as follows: target voltage at
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20 kV, first grid at 65% of target voltage, delayed extraction at 400 ns to obtain the best signal-
to-noise ratios and the best possible isotopic resolution. Mass calibration was performed using
external peptide standards purchased from AB Sciex. Each spectrum represents the sum of
3,000 laser pulses from randomly chosen spots per sample position. Raw data were analyzed
using the computer software provided by the manufacturers and are reported as monoisotopic
masses.
Cyanogen bromide cleavage reaction
CNBr cleavage was performed on purified recombinant ONC-DCless-H6-(PM)GKY20 pro-
tein. Sample was lyophilized and then resuspended in 0.2 M HCl at final concentration of 1.5
mg/mL. Cleavage was started by the addition of 100- and 400-fold molar excess of CNBr (40
mg/mL in 0.2 M HCl stock solution) over methionine residues, and the mixtures were incu-
bated in the dark at room temperature for 24 h. Reaction mixtures were dried under vacuum
and washed three times in 0.1 M acetic acid to allow CNBr evaporation. Samples were resus-
pended in 0.1 M acetic acid and the efficiency of cleavage was estimated by densitometric anal-
ysis of SDS-PAGE.
Antimicrobial assay
Antibacterial activity assays were carried out by i) agar dilution plate viable-count method [44]
and ii) broth microdilution method for antimicrobial peptides [50].
Agar dilution plate viable-count method was performed as previously described [44] with
minor modifications. A single colony of Pseudomonas aeruginosa (KK27) or Staphylococcus
aureus (ATCC 6538P) was suspended in 5 mL of Luria-Bertani (LB) medium (Becton, Dickin-
son) and overnight incubated at 37°C. When the cultures reached an OD600nm of 1 unit, they
were diluted 1:100 in 20 mM sodium phosphate buffer (NaP), pH 7.0. Samples were prepared
by adding 40 μL of bacterial cells to peptides at 0.1, 0.5, 1.0, 2.0, and 3.0 μM final concentra-
tions, in 1 mL of 20 mMNaP buffer, pH 7.0. Cells incubated with antibiotic (colistin 0.01 mg/
mL and ampicillin 0.05 mg/mL) were used as positive control, whereas cells incubated without
any antibiotics or peptide were prepared as negative control. Bovine serum albumin (BSA) was
tested at the same concentration of the peptides. Samples were incubated at 37°C for 4 hours
and dilutions (1:100 and 1:1000) of all the samples were placed on LB/agar medium and incu-
bated overnight at 37°C. The following day survived cells were estimated by colonies counting
on each plate and compared with controls. All compounds were tested in triplicate experi-
ments. Standard deviations were always less than 5%.
Minimal Inhibitory Concentration (MIC) was determined by broth microdilution method
following the protocol previously described for antimicrobial peptides [50] with minor modifi-
cations. Assays were carried out in Difco Nutrient Broth composed of 0.5% beef extract (w/v),
0.05% pepton and 0.25% NaCl, using sterile 96-well polypropylene microtiter plates (cat. 3879,
Costar Corp., Cambridge, MA). Twofold serial dilutions of peptides were carried out in the test
wells to obtain concentrations ranging from 100 μM to 0.2 μM. Bacteria were inoculated from
an overnight culture at a final concentration of ~ 5x105 CFU/mL per well and incubated over-
night at 37°C. MIC value was taken as the lowest concentration at which growth was inhibited.
Three independent experiments were performed for each MIC value. Controls included the
peptide antibiotic polymyxin B and vancomycin (Sigma, St. Louis, MO). MIC values were mea-
sured on: Escherichia coli DH5α, P. aeruginosa PAO1, P. aeruginosa PA14, B.megaterium
SF185, S. aureus ATCC 6538P from our laboratory strains collection and on Escherichia coli
ATCC 25922, Escherichia coli ATCC 35218, K. pneumoniae ATCC 700603 (kindly provided by
Eliana De Gregorio, University of Naples Federico II, Italy).
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Supporting Information
S1 File. Nucleotide and amino acid sequences. (A) ONC-(P)GKY20 and (B) ONC-DCless-
H6-(P)GKY20 fusion proteins. Onconase carrier (black); peptide (blue); linker region (red
underlined); His6-Tag (green). Amino acid substitutions in ONC-DCless-H6-(P)GKY20 pro-
tein sequence (B) were highlighted: glutamate residues (red), tyrosine residues (purple), leucine
residue (light blue), isoleucine residues (orange). The main restriction enzyme sites were also
reported: NdeI (turquoise); EcoRI (yellow); KpnI (grey); BamHI (green); SacI (pink). (C)
Sequence alignment of human prothrombin gene (GenBank: M17262) segment coding for
GKY20 (black) and the manually improved sequence (blue). Mutated codons were underlined
and nucleotide substitutions were highlighted in yellow.
(DOCX)
S2 File. Onconase secondary structure. Alpha helices (h) and beta strands (e) from Onconase
crystallographic structure [PDB:1ONC] are shown below the sequence. (A) Amino acid
sequence of ONCmutant (Onconase M23L, C104 delete); (B) amino acid sequence of
ONC-DCless mutant (Onconase M23L, D2E, D16E, D18E, C19Y, D20E, C30Y, D32E, C48L,
D67E, C68Y, C75Y, C87I, C90I, C104 delete). The amino acid substitutions are pointed out:
red, D2E, D16E, D18E, D20E, D32E, D67E mutations; grey, M23L mutation; turquoise, C19Y,
C30Y, C68Y, C75Y mutations; light green, C48L mutation; dark green, C87I, C90I mutations;
yellow, cysteine residues.
(DOCX)
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